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Abstract 
 
The isoform 2 (NCX2) of sodium–calcium exchanger family is involved in the 
regulation of the sodium and calcium homoeostasis of neuronal and glial cells. In 
particular, NCX2 participates in cytosolic Ca2+ clearance after spike and synaptic 
plasticity, whereas under pathophysiological conditions it exerts a 
neuroprotective effect in stroke.  
To investigate the genetic regulation of NCX2, we identified its minimal 
promoter in the region of 1200 bp, localized between slc8a2 and kptn genes. 
This sequence induced the transcription of a reporter gene in two different 
neuronal cell lines, PC12 and SHSY, that express the endogenous NCX2 
mRNA. By contrast, the promoter failed to induce the transcription in BHK and 
U87 cell lines that do not express NCX2 under control conditions. These results 
reinforced the similarity observed in the transcription activity of the endogenous 
NCX2 promoter and the region we identified and cloned. In addition, we found, 
by in silico analysis, a great number of putative binding sites for transcription 
factors in the promoter sequence. These predicted sites showed high matrix 
identities and were found conserved among three considered species, including 
rat, mouse, and human genome. Interestingly, many of these TFs are expressed 
in the CNS where NCX2 is localized, suggesting a possible role in the regulation 
of the expression of this exchanger under physiological and pathophysiological 
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conditions. In particular, the overexpression of the transcription factors Sp1, 
Sp4, and CREB displayed a stimulatory effect on NCX2 promoter activity under 
control conditions as measured by luciferase reporter assay, whereas SREBP1 
exerted an inhibitory effect. Notably, we found that Sp1 and Sp4 share the same 
molecular determinant localized very close to the transcription start site of the 
NCX2 promoter, while CREB1 exerted its effect at the beginning of the cloned 
sequence. We also evaluated the possible subregion where SREBP1 exerted its 
inhibitory effect on the transcription activity.  
Interestingly, the transfection of these TFs in U87 cell line failed to express the 
endogenous NCX2, thus letting us hypothesize the participation of other 
regulatory mechanisms, such as epigenetic, in the downregulation of NCX2 
transcription. In fact, we found some epigenetic differences between PC12 and 
L6 cells, expressing or not expressing, respectively, the endogenous NCX2 gene. 
In particular, we reported significant differences in CpG methylation in the 
above-mentioned cell lines on the antiporter promoter. In this regard, 5’-
Azacytidine, by imparing genomic DNA methylation, induced the expression of 
NCX2 in U87 cells. 
In conclusion, all these results showed that: (1) the basal expression of NCX2 is 
dependent on the methylation status of its promoter and (2) NCX2 expression 
can be up-regulated or down-regulated by several transcription factors found in 
the CNS.  
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Chapter 1: Introduction 
1.1 Hypothesis  
This PhD thesis is based on the hypothesis that the promoter regulating the 
transcription of the gene encoding for the isoform 2 of the Na+/Ca2+ exchanger 
protein (NCX2) is located in the intergenic region ranging between slc8a2 and 
Kptn genes. 
1.2 Objectives  
 To identify the minimal promoter of slc8a2 gene encoding for NCX2 
 To identify several transcription factors involved in the regulation of 
NCX2 expression 
1.3 Thesis organization 
While the first chapter of this thesis was a brief introduction of the thesis, with 
the hypothesis and objectives of this research work, the second chapter of this 
thesis begins a detailed literature review of the sodium/calcium exchanger 
(NCX), particularly of the second isoform (NCX2), on its distribution, regulation 
and relevance under physiological and pathophysiological conditions. Chapter 3 
presents a brief review of the eukaryotic transcription regulation and in silico 
approaches to identify gene promoters. Chapter 4 describes objectives and 
significance of this thesis. Chapter 5 presents the materials and methods used for 
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all experimental procedures. Chapter 6 describes the feature predictions on the 
putative NCX2 promoter, experiments validating this hypothesis and all the 
results obtained. Chapter 7 contains the discussion of the results obtained.  
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Chapter 2: Literature review on NCX2 
2.1 Background  
The sodium-calcium exchanger (NCX) is an antiporter of Na+ and Ca2+ ions 
across the plasma membrane widely distributed in mammalian cells. It represents 
an essential component of Ca2+ homoeostasis under physiological and 
pathophysiological conditions in both cardiovascular and neurological tissues. Its 
activity was described for the first time in the late 1960’s in the heart (Reuter and 
Seitz 1968) and in squid axon (Baker, Blaustein et al. 1969). However, the first 
Na+-Ca2+ exchanger isoform was isolated (Philipson, Longoni et al. 1988), 
cloned and characterized (Nicoll, Longoni et al. 1990) 20 years later. Nowadays, 
three isoforms of NCX family have been identified, cloned and functionally 
characterized from several mammals including mouse (Conway, Wang et al. 
2002), rabbit (Armoundas, Rose et al. 2007) guinea pig (Niggli and Lederer 
1991) and dog (Sipido, Volders et al. 2002). These isoforms, named as NCX1, 
NCX2, and NCX3, are encoded by three different genes, slc8a1, slc8a2, and 
slc8a3, respectively, with a high grade of conservation among different 
mammalian species. NCX1, NCX2, and NCX3 share ~70% of amino acid 
sequence identity. NCX1 is expressed ubiquitously in the organism (Nicholas, 
Yang et al. 1998); NCX2 shows an expression restricted in central nervous 
system (CNS) (Li, Matsuoka et al. 1994); NCX3 is expressed in the CNS, 
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immune system and skeletal muscle (Staiano, Granata et al. 2009). On the other 
hand, invertebrates seem to present only a single NCX ortholog, based upon 
investigation in arthropods (Dyck, Maxwell et al. 1998) and molluscs (He, Tong 
et al. 1998). 
 
2.2 Molecular Biology and Topology of NCX2 
Among the three exchangers, NCX1 is the most studied on molecular detail. 
Since NCX1 was studied in cardiomyocytes were it is highly expressed, this 
isoform is also referred as the cardiac isoform of the sodium/calcium exchanger. 
Initially, on the basis of the amino acid sequence, it was proposed a topological 
model of 12 hydrophobic transmembrane segments (TMS) separated by a large 
intracellular loop named ‘f loop’ (Philipson, Longoni et al. 1988; Nicoll, 
Figure 1: Cartoon representation of NCX topology. NCX is composted by 10 transmembrane 
segments (TMS). TMS 5 and 6 are separated by a citosolyc intracellular loop 
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Longoni et al. 1990). However, this model was subsequently corrected to 10 
TMS based on the crystal structure of the archaebacterial ortholog NCX_Mj 
(Ren and Philipson 2013). In all NCX isoforms, TMS can be grouped in an 
amino-terminal domain, that comprises the first 5 TMS, and a carboxy-terminal 
domain that includes the last 5 TMS. Mutagenesis experiments indicate that 
specific regions of the transmembrane segments, named 1 and 2 repeats, are 
critical in the ion transport process (Nicoll, Quednau et al. 1996). In addition, all 
the exchanger isoforms show an initial hydrophobic segment that represents a 
signal peptide cleaved during initial processing in the endoplasmic reticulum 
(Durkin, Ahrens et al. 1991; Hryshko, Nicoll et al. 1993) and both N- and C-
terminals exposed to the extracellular side. On the other hand, although specific 
experiments were not conducted on NCX2 and NCX3 isoforms, scientific 
community considers similar structures for these two isoforms since they share a 
high amino acid sequence identity and several common biophysical properties. 
 
2.3 Brain distribution of NCX in Central Nervous System 
In CNS, NCX1, NCX2 and NCX3 are widely expressed in neurons, glia, and 
microglia with several splicing variants that appear to be selectively expressed in 
different regions and cellular populations of the brain. In particular, NCX1 is 
highly expressed in pyramidal neurons of the motor cortex, while NCX2 is 
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expressed at increased cortical somatosensory level. In hippocampus NCX 
isoforms are expressed at good levels in dentate gyrus, CA1, CA2 and CA3 areas 
(Papa, Canitano et al. 2003). NCX isoforms are expressed at the mesencephalic 
level and in important areas for the control of extrapyramidal motor coordination 
of the basal ganglia. NCX1 signal is found in the compact part of the substantia 
nigra where the bodies of the dopaminergic cells are localized, while in the 
nucleus accumbens are expressed all isoforms of NCX (Canitano, Papa et al. 
2002; Papa, Canitano et al. 2003). 
2.4 NCX family genes 
NCX family includes three different genes that encode three proteins: NCX1 
(Nicoll, Longoni et al. 1990), NCX2 (Li, Matsuoka et al. 1994) and NCX3 
(Nicoll, Quednau et al. 1996). NCX1 mRNA is found in 15 different alternative 
splicing forms that seems to be tissue or cell specific (Quednau, Nicoll et al. 
1997; Philipson and Nicoll 2000), whereas NCX3 mRNA is found in 6 different 
splicing variants (Gabellini, Bortoluzzi et al. 2002). The region subjected to 
splicing variance is localized in the long intracellular loop f and comprises about 
110 amino acids (Kofuji, Lederer et al. 1994). To date, alternative splicing forms 
of NCX2 were not identified. 
Genes encoding for NCX1 are often long, about  long 200 kb (Kofuji, Lederer 
et al. 1994; Scheller, Kraev et al. 1998), and are dispersed among different 
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species, since it located on chromosome 2 in human, chromosome 17 in mouse, 
chromosome 6 in rat. The entire gene is organized in twelve exons: first exon is 
a non-coding sequence and contains part of the gene promoter; the exon 2 
together with exon 12 represents the major part of mRNA transcript (Kraev, 
Chumakov et al. 1996); exons 3-8,  also indicated with the letters from A to F, 
are combined in different splicing isoforms to confer the tissue-specificity 
(Nakasaki, Iwamoto et al. 1993; Lee, Yu et al. 1994). In particular, exons A and 
B are mutually exclusive (Kofuji, Lederer et al. 1994), the presence of exon D is 
necessary for all the spliced isoforms, while the exons C, E and F may be present 
or not in the mature RNA sequence. Generally, in excitable cells such as 
cardiomyocytes and neurons, it is expressed exon A, while the exon B is 
expressed in non-excitable cells including kidney, stomach and skeletal muscle 
cells (Quednau, Nicoll et al. 1997).   
The expression of NCX1 gene is controlled by three different tissue-specific 
promoters, named brain, heart and kidney promoters (Barnes, Cheng et al. 1997; 
Nicholas, Yang et al. 1998). The heart promoter does not possess the "TATA" 
box region, one of a hallmark of the presence of a putative promoter, but it is 
characterized by multiple transcriptional start sites. Such promoter possesses two 
consensus sequences for fos and jun (AP-1) transcription factors and two 
GATA-family binding sites (Nicholas, Yang et al. 1998). On the opposite, the 
promoter of the renal variant of NCX1 presents one "TATA box" and consensus 
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sequences for tissue-specific transcription factors. The promoter of brain variant 
is particularly rich in GC nucleotides and induces high level of expression in 
neuronal cells, and a lower level of expression almost in all other non-excitable 
tissues. Cerebral promoter does not possess the "TATA box" and contains many 
binding sites including Sp1, AP2, NF-kB, HIF-1, and REST consensus 
sequences (Nicholas, Yang et al. 1998; Sirabella, Secondo et al. 2009; Valsecchi, 
Pignataro et al. 2011; Formisano, Guida et al. 2015) 
The gene of the third isoform of NCX is located on chromosome 12, 14 and 6 
in mouse, human, and rat, respectively. It consists of 9 exons very similar to that 
observed in NCX1. In fact, NCX3 gene lacks the homologous exons 6-8, named 
D-F, if compared with NCX1 gene (Gabellini, Bortoluzzi et al. 2002; Gabellini, 
Bortoluzzi et al. 2003; Gomez-Villafuertes, Torres et al. 2005). 
NCX3 possesses a single promoter whose 5'UTR region is rich in GC 
nucleotides and its minimal functional region contains all the specific sequences 
for the expression in neuronal and muscle cells (Gabellini, Bortoluzzi et al. 
2003). The main consensus sequence for the tissue-specific expression of NCX3 
is the cAMP response element (CRE), although alone is not enough to induce the 
transcription in vivo (Gomez, Gabellini et al. 2004). NCX3 promoter also 
features a double-inhibitory sequence known as downstream regulatory element 
(DRE). These two sequences confer an auto-regulatory mechanism to the gene 
inasmuch, when NCX3 activity is very high and thus intracellular calcium 
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concentration falls below a certain level, the affinity of DREAM for the DRE 
sequences increases, and consequently inhibits the transcription of NCX3 gene. 
(Gomez, Gabellini et al. 2004). 
The gene coding for NCX2, instead, consists of 10 exons and has been 
localized on chromosome 7, 19 and 1, in mouse, human, and rat, respectively. 
The knowledge of the localization of NCX2 gene and the characterization of its 
regulatory properties was not accomplished yet (Kraev, Chumakov et al. 1996), 
and it is the object of the present study. 
 
2.5 Relevance of Na+/Ca2+ exchanger activity under physiological and 
pathophysiological conditions 
The primary physiological role of NCX is Ca2+ efflux from the cell. This 
activity, known as “forward mode”, contributes to the restoration of the 
intracellular level of Ca2+ after its physiological increase in concentration. This 
process is driven by the cellular Na+ gradient produced by the Na+/K+ pump. 
According to the proposed model for NCX transport under physiological 
conditions, extracellular Na+ binds to the transport site, is internalized and 
released inside the cell. Afterward, Ca2+ ion binds its translocation site, is 
internalised into the membrane and is released into the extracellular space 
(Hilgemann, Matsuoka et al. 1992). By contrast, NCX can also work in a 
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“reverse mode” extruding 3 ions of Na+ and intruding 1 ion of Ca2+. This mode is 
essential to restore the Na+ concentration under some physiological or 
pathophysiological conditions, for instance, after a membrane potential 
depolarization. To date, classical exchange stoichiometry is 3:1 (Na+:Ca2+), but, 
however, this physiological rate might range from a minimum of 1:1 to a 
maximum of 4:1 (Kang and Hilgemann 2004). 
Under pathophysiological conditions, NCX often works in the reverse mode, 
causing Ca2+ influx. This inward flow of Ca2+ can contribute to calcium 
overload, which may ultimately lead to myocardial damage resulting from 
arrhythmogenesis (Pogwizd 2003), cellular ultrastructural changes, disruption of 
membrane integrity and mitochondrial dysfunction (Bers 2008). Dysregulation 
of cellular Ca2+ homeostasis is also a common feature in a variety of 
neurological disorders, including stroke, epilepsy, and trauma, where activation 
of Ca2+-dependent proteases, such as calpains, and activation of nitric oxide 
production lead to excitotoxic neuronal death (Araújo and Carvalho 2005; 
Kintner, Wang et al. 2007). Inhibition of the reverse mode of NCX may be 
useful in maintaining physiological levels of cytosolic Ca2+ and protecting cells 
from death (Matsuda, Arakawa et al. 2001) 
Alteration in the regulation of ionic homoeostasis is one of the main event 
occurring during neuronal damage. In this regards, NCX plays an important role 
in maintaining homoeostasis of the intracellular Ca2+ and Na+ ions under some 
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pathophysiological conditions. For these reasons, NCX is considered as a 
possible drug target to slow the course or to prevent the pathogenesis of some 
serious diseases characterized by loss of ionic homeostases, such as Alzheimer's, 
multiple sclerosis, epilepsy, ischemic heart, kidney, and brain diseases. In 
particular, during cerebral ischemia, there is a non-supply of oxygen and glucose 
that, in turn, leads to a marked reduction of ATP levels. ATP loss causes the 
block of the two ATP-dependent transport systems: the Na+/K+ ATPase and the 
Ca2+ ATPase. Consequently, there is a homoeostasis imbalance of these ions 
with progressive increase of their intracellular concentrations that cause necrosis 
or apoptosis of neurons after anoxia. Under these conditions, it is clear the 
importance of the role played by membrane proteins that do not make direct use 
of ATP. In fact, an increase in the activity of NCX may restrict or counteract the 
excessive accumulation of intracellular Ca2+ and Na+ and, consequently, 
facilitate neuronal survival. In recent studies, it was shown that the knocking-
down of NCX1 or NCX3 (Pignataro, Gala et al. 2004), or the deletion of NCX3 
(Molinaro, Cuomo et al. 2008), causes a marked increase in infarct volume after 
cerebral ischemia, induced by middle cerebral artery occlusion. Even the use of 
inhibitors of NCX worsens the cerebral infarction, while the administration of 
compounds that enhance NCX activity reduces the area of cerebral infarction 
(Molinaro, Cuomo et al. 2008). 
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The absence of NCX2 produces a delay in the cytosolic Ca2+ after a 
depolarization event in hippocampal neurons. As consequence of this 
phenomenon, paired-pulse facilitation (PPF) and post-tetanic potentiation 
resulted enhanced. Furthermore, NCX2 knockout mice show an improved 
plasticity at the presynaptic level (Jeon, Yang et al. 2003). As the effect of this 
potentiation, NCX2 knock-out mice show an improved performance in learning 
and memory tasks that depends on from the hippocampus, such as water-maze 
and fear conditioning. This evidence suggests that NCX2 may play an important 
role in disease involving a cognitive impairment such as Alzheimer’s and 
Parkinson’s diseases. On the other hand, deletion of NCX2 increases the 
hippocampal susceptibility to the ischemic insult and a worsening of stroke 
outcome (Jeon, Chu et al. 2008).  
Interestingly, NCX2 was found to be silenced or disrupted in glioma. Indeed, 
this tumour presents a frequent loss of heterozygosis in the long arm of 
chromosome 19 (19q13.3) where NCX2 is localized (Qu, Jiao et al. 2010). This 
genetic deletion is combined with an increasing of the methylation in this locus 
(Ceccarelli, Barthel et al. 2016). Take together this evidence suggests that the 
transcriptional silencing of NCX2 may be mediated by an epigenetic 
modification and that NCX2 may play a role to hamper the tumour development. 
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Chapter 3: Literature review on gene promoters 
3.1 Eukaryotic regulation of the transcription  
A gene is a unit of heredity that may influence the outcome of an organism’s 
traits. These informative units are located at specific sites of a chromosome as a 
segment of DNA and they encode instructions necessary for the synthesis of 
proteins that are responsible for almost all biological processes and hence, 
phenotypic traits of an organism. Eukaryotic genes consist of alternating 
sequences of exons and introns. Typically, the extremities of a gene are 
characterized by sequences that are transcribed but not translated in proteins: 5’ 
and 3’ untranslated regions (UTRs). Region upstream the transcription starting 
site together with the 5’ UTR is often involved in the regulation of the gene 
transcription and expression (Weaver and Hedrick 1997), and might contain the 
gene promoter. The promoter is influenced by several regulatory DNA-binding 
molecules. The outcome regulation of these elements depends on the specific 
affinities and a unique distribution of particular DNA sequences on the promoter 
(Segal and Widom 2009). These sites are structured to be recognized by 
transcription factors (TFs), a class of proteins or protein complexes with the 
ability to bind specific DNA sequences usually located in the gene promoter, 
called cis-acting elements. 
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3.2 The Eukaryotic Transcriptional Machinery 
The machinery of gene transcription requires being accurate and fined 
controlled by the cell. A high number of factors have involved the composition 
of the complex that leads the RNA polymerase II to the transcription starting site 
(TSS) to initiate mRNA synthesis. These factors are grouped into general (or 
basic) transcription factors (GTFs), promoter-specific activator proteins 
(activators), and co-activators according to their activity or localization. GTFs 
are assembled to construct the basal transcription machinery necessary and 
sufficient to initiate the transcription. This transcription machinery includes 
RNA polymerase II and a variety of auxiliary components, such as TFIIA, 
TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. These factors join the transcription in a 
precise sequence and finally assembly the pre-initiation complex (PIC), which 
directs RNA polymerase II to the TSS. The first step in PIC assembly is the 
binding of TFIID to the promoter. This factor is composed of different subunits 
consisting of TATA-box-binding protein (TBP) and a set of TBP associated 
factors (TAFs). The following steps include promoter melting, clearance, and 
escape, before the formation of a fully functional RNA polymerase II elongation 
complex. However, this transcription machinery does not initiate gene 
transcription. In fact, this control mechanism lays the scaffold structure 
composed by TFIID, TFIIE, and TFIIH on the binding sequence. Gene 
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transcription effectively starts when another RNA polymerase II-TFIIF-TFIIB 
complex is recruited (Weaver and Hedrick 1997). 
3.3 Core Promoter 
The minimum sequence that initiates DNA transcription is often located 
upstream the TSS and it named core promoter. This sequence frequently is ~40 
nucleotides long and contains binding sites for transcription factors involved in 
the formation of PIC complex. These binding sites can include TATA (TATA-
box), CAAT (CAAT-box) sequences, upstream or downstream TFIIB 
Recognition Element (BREu or BREd), Initiator (Inr), Motif Ten Element (MTE), 
Downstream Promoter Element (DPE), Downstream Core element (DCE), and X 
Core Promoter Element 1 (XCPE1). The Inr sequence is the most common cis-
element, found in nearly half of the focused promoters. Its consensus sequence 
consists of YYANWYY (where Y is C or T, W is A or T and N is A, T, C or G) 
and the adenine represents the +1 from TSS. This motif showed a selective 
signal for the subunit TAF1 and TAF2 of the Transcription Factor II D (TFIID) 
(Chalkley and Verrijzer 1999) and can be associated to other core element motifs 
such as TATA-box, DPE or MTE. TATA-box was the first identified and the 
most investigated cis-acting element, its presence is restricted to the 10-15% of 
the mammal’s promoters. The position of this motif depends on the tissue 
specificity of the promoter, but generally, is located at position -31 or -30 from 
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the +1 of the Inr. This motif is bound by the TATA-box Binding Protein (TBP), 
a subunit of transcription factor TFIID. The two sequences BREu and BREd 
participate in the composition of the initiator mechanism together with TATA 
boxes. These motifs are bound by TFIIB to complete the TFIIB-TBP promoter 
complex. Both DPE and MTE are signals for TFIID alternative to the TATA-box 
and the distance of those motifs from Inr sequence is generally crucial for the 
optimal construction of TFIID-based initiation machinery 
Promoters provided with more alternative TSS are classified as “dispersed 
promoters”, whereas promoters that present a single TSS and either TATA or 
CAAT boxes are classified as “focused promoters”.  
Dispersed promoters generally lack BRE, TATA, DPE, and MTE motifs 
Figure 2. Cartoon representing the relative position of core promoter elements: BREu and 
BREd are located upstream and downstream of the TATA box, respectively. Inr and XCPE1 are 
located on the transcriptional starting site (TSS). MTE, DPE and the alternative initiation motif 
DCE are localized downstream the TSS. 
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(Juven-Gershon and Kadonaga 2010) and present multiple Inr combined with 
GC-boxes or other binding site for regulatory elements. 
Focused promoters can present the combination of Inr and TATA-box, DPE 
or MTE motifs. Alternatively, focused promoter can lack Inr signal and can 
present DCE, XCPE1 or XCPE2 motifs in association or not with a TATA motif. 
However, the presence of DCE, XCPE1 or XCPE2 motifs is frequent in lower 
species, whereas these consensus sequences are present only in 1% of human 
promoters. Notably, DCE, XCPE1 and XCPE2 are mostly present in TATA-less 
human promoters. However, statistical analysis on 10,000 predicted promoters 
has shown that the focused promoters are not frequent as though before 
(Gershenzon and Ioshikhes 2005).  
The mechanisms of gene transcription are different between focused and 
dispersed promoters. Their molecular dynamics are currently under 
investigations of basic research. 
3.4 Proximal Promoter 
The proximal promoter is generally defined as a regulatory sequence of 4 or 5 
hundred bases that modulates gene transcription, and contains several specific 
transcription factor binding elements. Typically, this sequence confers the tissue 
specificity of a gene or allows genes to be selectively expressed in response to 
certain environmental conditions. TFs that bind these elements can deform 
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DNA, moving the distal promoter closer to the basal transcription complex and 
thus influence transcription machinery. Proximal promoters can enrol enhancers 
or silencers to regulate the transcriptional activity of the core promoter (Atchison 
1988). 
3.5 Distal regulatory elements 
Distant regulatory elements are DNA sequences that participate in the regulation 
of gene transcription and that can be located thousands of base pairs distant from 
the TSS. In particular, distal regulatory elements can be located in the intergenic 
regions upstream of a gene, in introns, in a region downstream of the 3’UTR or 
even in a far chromosome region (Weaver and Hedrick 1997). Depending on 
Figure 3. Cartoon representing focused (on the left) and dispersed (on the right) promoter. 
(A) Focused promoters are characterized by the presence of a single transcription starting site and 
an initiator complex (blue) for the RNA polimerase II (green). (B) dispersed promoters display
multiple transcription starting sites with relative initiator motifs (green) and binding sequences for 
specific factors (red) 
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their activity and position, distant regulatory elements can be grouped in: 
enhancers, silencers, insulators and locus control regions. Enhancers amplifies 
the expression mediated by a single or more independent promoters. A prototype 
model of an enhancer consists of 10 to 15 transcription factor binding sequences 
(TFBS) of at least two or three cooperative transcription factor families. The 
composition of these enhancers is analogous of a proximal promoter. The 
interaction between the enhancer and the promoter is regulated by several 
control mechanisms. First of all, the efficiency of the stimulation strictly depends 
on the position of the enhancer from the target promoter. A second mechanism 
consists in the interference of a structure known as insulator. In addition, the 
pattern of transcription factors on the promoter must reflect the appropriate 
elements of interaction on the enhancer to allow the correct tethering of the 
structure.  Mutations of enhancer sequences, or of their TFs, may result in some 
pathological conditions such as preaxial polydactyly (Lettice, Heaney et al. 
2003) or Van Buchem diseases (Loots, Kneissel et al. 2005). 
Silencer sequences, besides the negative effect on the transcription, are 
provided with many analogies with enhancers. Silencer can downregulate the 
promoter activity in a position- and orientation-dependent manner, as well as the 
enhancer. In addition, TFs that bind these structures are typically repressor or 
even can be both repressor or activator, depending on the target promoter. 
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Recent studies suggest that silencers can inhibit transcription by compromising 
the formation of the PIC complex (Chen and Hampsey 2002). 
Insulators are DNA sequences that block the activation of a gene owing to a 
collateral unspecific activity of neighbours genes or stimulatory structures. They 
are usually composed of a cluster of binding sites for zinc finger proteins. 
CCCTC-binding factor (CTCF) is the only known factor mediating an insulator 
activity in vertebrates. Insulators may also act as a barrier preventing the spread 
of chromatin condensation to genes that need to remain actives. A typical 
insulator can present only one of the two types of control described above 
(Recillas-Targa, Pikaart et al. 2002). 
Figure 4: Cartoon representing the regulatory elements of a promoter: this representation 
displays a core promoter element (cyan), proximal promoter (purple), locus control region (orange), 
insulator (blue), silencer (red) and enhancer (green). 
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3.6 Transcription Factors 
RNA polymerase II machinery initiates gene transcription by using core 
promoters. This reaction can be also obtained with high efficacy in a reaction 
solution in vitro. However, there are many regulatory proteins that can 
participate in the regulation of the transcription efficacy in vivo. This can be 
achieved by the interaction of TFs with proximal and/or distal promoters and 
thus by modulating the assembly of disassembly of the basal transcription 
mechanism. TFs are classified as activators, repressors or co-regulators 
depending on their mechanisms of interaction with the promoter and other 
proteins. In particular, TFs are considered activators or repressors according to 
their positive or negative effect on the transcription process. However, in most of 
the cases TF proteins can exert both activatory and inhibitory effects depending 
on specific cellular contexts. As regard co-regulators, these proteins modulate 
the effect of other TFs, or DNA binding proteins, via protein-protein interaction 
without a direct DNA bind. Co-regulators can be subclassified as co-activators 
or co-repressors depending on the effects of their interaction with the 
transcription efficiency.  More important, they represent the link that mediates 
extra-cellular and intra-cellular signals to the transcription of target genes. These 
kinds of co-regulators exert their activity on the transcriptional machinery via 
enzymatic functions. For instance, co-regulators can change the chromatin 
environment of regulatory regions, or can mediate phosphorylation, 
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ubiquitinylation or sumoylation of target transcription factors (Lonard and 
O'Malley 2005). 
 
3.6.1 cAMP response element binding protein (CREB) 
CREB is a transcriptional factor that was first isolated in undifferentiated 
neuron-like PC12 cells (Montminy, Sevarino et al. 1986). This TF is a member 
of Basic Leucine Zipper Domain (bZIP) superfamily able to bind a DNA 
sequence consisting of the palindromic core 5’-TGACGTCA-3’, known as 
cAMP response element (CRE) (Mayr and Montminy 2001). CREB family also 
includes the transcription factor CRE modulator (CREM) and Activation 
Transcription Factor 1 (ATF-1). Each member of this family is encoded by a 
different gene that contains at least two highly conserved regions. One region is 
composed of a ZIP domain followed by one or two structures that bind CRE 
motifs, whereas the central part of the protein is characterized by a kinase-
inducible domain (KID) containing several protein kinase A (PKA) 
phosphorylatable residues. Frequently, the KID domain is delimited by two 
glutamine-rich regions (Q1 and Q2) that mediate the protein-protein interaction 
among CREB family members. These TFs can form both homodimers and 
heterodimers, however, the CREB homodimer complex presents the highest 
transcriptional efficacy (Dworkin and Mantamadiotis 2010). 
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Different metabolic pathways can activate CREB to enhance or to initialize 
the transcription of several target genes. CREB binds almost 4000 known 
promoters (Zhang, Odom et al. 2005), however, to date, it is still unknown how 
it is able to mediate distant responses from a very high number of different 
physiological and pathophysiological signallings.  
Phosphorylation on the KID domain is the key mechanism of CREB 
regulation. Indeed, the counteracting effect of protein kinases and phosphatases 
regulate the activity of this TF in important processes in which it has a central 
role, including cell cycle (Liu, Begley et al. 2014), cell death (Martin 2010), 
DNA damage (Abreu, Kumar et al. 2013) and neurogenesis (Faigle and Song 
2013). The CREB-mediated transcriptional regulatory machinery can require 
additional accessory proteins including PTEN or CREB-binding protein (CBP). 
In particular, CBP joins the machinery as chromatin remodeler, unwinding the 
promoter and providing the access to RNA polymerase II (Chan and La Thangue 
2001). If this protein does not participate in the CREB-mediated transcription 
complex, the target genes remain transcriptionally silent (Merz, Herold et al. 
2011). 
CREB binding motif may present an additional regulatory element that 
consists in the presence a central CpG dinucleotide. The methylation of this 
group is able to sterically impair the binding to the CRE element, even when 
CREB is activated by phosphorylation (Ortega-Martínez 2015). 
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In last few decades, an increasing amount of studies demonstrated that CREB 
plays a pivotal role in several regulatory processes of the nervous system. In 
particular, during embryogenesis, this TF participates to the differentiation of the 
neuronal progenitor cells and to the development of brain. In the adult, CREB is 
involved in neuronal plasticity and consolidation of long-term memory 
(Yamashima 2012). CREB can be also activated in response to a harmful 
stimulus enhancing transcription of pro-survival genes. The protective effect of 
CREB-activated genes depends on phosphorylation span of the TF. For instance, 
in hippocampal dentate gyrus (DG), the increased permanence of CREB in the 
phosphorylated form causes more neuroprotection after cerebral ischemia as 
compared with CA1 area (Mabuchi, Kitagawa et al. 2001). 
 
3.6.2 Specific Protein (SP) Family  
Sp-family includes a wide group of transcription factors involved in the 
expression of genes that participate in the regulation of several biological 
functions including brain development, cell growth, apoptosis, and 
differentiation. Members of this family are generally able to bind GGGGCGGG 
(GC-box) and the related GGTGTGGGG (GT/CACC-box) sequences.  
Members of this family are characterized by three C2-H2 zinc fingers in the C-
terminus of the protein, whereas N-terminal region presents glutamine-rich 
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domains in proximity to the serine/threonine stretches that are involved in the 
binding with co-regulator proteins. The N-terminal region also contains an 
endoproteolytic cleavage site necessary for proteasome-dependent degradation. 
The C2H2-type zinc finger region is structured by 81 amino acids, mediates DNA 
binding, and is the most highly conserved part of the proteins. Among Sp family 
members, Sp1, Sp3, and Sp4 are most closely related each other than Sp2. In 
addition, the zinc fingers of Sp1/3/4 present higher affinity to GC-boxes if 
compared with Sp2 (Suske 1999). 
 
3.6.2.1 Sp1 
Sp1 was the first isoform of the Sp family to be identified and it is considered 
the prototypic member (Kadonaga, Carner et al. 1987). Sp1 gene encode for a 
105 kDa protein that is ubiquitously expressed in the mammal cells. The 
expression of this protein is higher in the astrocytes than in the neurons in the 
Figure 5 Topology of Sp1, Sp3 and Sp4: Coloured boxes indicate glutammine rich domains 
(green), serine/threonine residues (blue), inhibitory domains (red) and zinc finger domains (black). 
Amino acid length of the respective protein is indicated on the right. 
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brain. Sp1 presents a typical structure of Sp family, indeed, it has two activatory 
glutamine-rich regions in the center part of the protein and an inhibitory domain 
related to a proteasome-dependent degradation in the N-terminus part (Gill, 
Pascal et al. 1994; Murata, Kim et al. 1994; Su, Roos et al. 1999). Zinc fingers 
and the nearby area are necessary to bind multiple CG-boxes and form homo- or 
hetero-typic complexes with other transcription factors and co-regulators (Suske 
1999). 
To date, many mechanisms of DNA binding have been postulated for this TF. 
In particular, Sp1 can bind, with synergic activity, sequential consensus 
sequences of gene promoters as homo-, or hetero-multimer with Sp4 
(Mastrangelo, Courey et al. 1991; Su, Roos et al. 1999). In addition, Sp1 seems 
to be regulated by the methylation status of target DNA. In fact, methylation of 
regulatory GC-boxes outside the binding site produces a significant decrease in 
the affinity of this TF. On the other hand, methylation of the CpG dinucleotide 
inside the binding motif does not reduce the Sp1 affinity for the site. 
Basal activity of Sp1 participates in the transcription of housekeeping, tissue-
specific and cell-cycle-related genes including core promoter transcription 
factors (Dunah, Jeong et al. 2002). Sp1 also exerts a role in development 
processes since knock-out animals present abnormal embryogenesis and die in 
the early stage of fetus formation (Marin, Karis et al. 1997). Among Sp1 target 
genes there are several receptors, such as NMDA and D2 dopamine receptors, 
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and proteins regulating neurotransmission, such as MAO-B (Yajima, Lee et al. 
1998; Chen, Kundakovic et al. 2007), that might exert a role in CNS disorders. 
Indeed, some human disorders can be related to Sp1 alteration or misregulation. 
A wide amount of studies suggests that Sp1 and its homologs, Sp3 and Sp4, 
participate to brain tumour development. In fact, their increased expression is 
frequently associated with a negative prognosis in several brain tumours such as 
glioma (Safe and Abdelrahim 2005). Sp1 also exerts a role in several 
neurodegenerative disorders such as Huntington’s disease, (Dunah, Jeong et al. 
2002), Alzheimer’s (Santpere, Nieto et al. 2006), multiple sclerosis 
(Kristjansdottir, Sandling et al. 2008) and psychiatric disorders. In addition, Sp1 
was found down-regulated in certain brain areas involved in the regulation of the 
social behaviour, such as striatum. On the other hand, Sp1 expression increases 
in the parietooccipital cortex, which misfunction in schizophrenia leads to 
hallucination and inability to planning (Ben-Shachar and Karry 2007). 
Sp1 is activated during oxidative stress and hypoxia (Ryu, Lee et al. 2003; 
Miki, Ikuta et al. 2004) where it regulates the activity of neuroprotective and 
neurodetrimental genes. In particular, Sp1 increases transcription of CD39, that 
enhances cell survival (Eltzschig, Köhler et al. 2009), after hypoxic conditions, 
and enhances the transcription of the Sur1-regulated Ca2+-ATP channel that 
leads to the enlargement of ischemic edema. Sp1 also act as co-regulator of 
ATF3, c-Jun, and STAT3 to activate injury-inducible genes in damaged neurons 
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(Kiryu-Seo, Kato et al. 2008). Despite the role of Sp1 under CNS 
pathophysiological conditions is constantly reinforced by new evidence, the 
mechanisms underlying its activity, especially in stroke, are not been determined 
yet.  
 
3.6.2.2 Sp3 
Sp3 was cloned for the first time in 1992 by two different groups (Kingsley 
and Winoto 1992; Hagen, Müller et al. 1994; Abreu, Kumar et al. 2013). As 
mentioned before, Sp3 presents high homology with Sp1 and the same activatory 
and inhibitory domains. Sp3 is expressed ubiquitously and knock-out mice 
present an impaired post-natal development and ossification process. In addition, 
this TF, as its homologous Sp1, is also involved in the regulation of brain-related 
genes with a key role in several neurological and behavioural disorders including 
D2 (Yajima, Lee et al. 1998) dopamine receptors, MAO-B (Shih and Chen 2004) 
and GABA-A receptor subunit α4 (Ma, Song et al. 2004). Although literature 
presents less information on Sp3 involvement in brain disorders than is reported 
for Sp1, the investigation on the role of this protein is still at the beginning. 
As regards the activity of Sp3, this isoform can act as repressor, rather than 
activator, of many target genes and is able to positively or negatively modulate 
the effect of other Sp-family members. For instance, in promoters that present 
multiple Sp1 sites, Sp3 can hamper the Sp1/4-mediated enhancement by two 
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ways: (1) it can compete for the same binding motif; (2) it can block the synergic 
Sp1 modulation by occupying a proximal regulatory GC-Box (Yu, Datta et al. 
2003). However, Sp3 shows higher activatory effect, if compared with Sp1, on 
some gene promoters under specific conditions. For instance, p21 promoter is 
provided with six Sp1 binding sites, but Sp3 activates the gene transcription 
better than Sp1 (Gartel, Ye et al. 2001).  
In addition, Sp3 is provided with an important post-transcriptional regulation 
mechanism, including sumoylation or acetylation at the level of regulatory 
domains, that participate to the repressor or activator activity of the TF (Braun, 
Koop et al. 2001; Ammanamanchi, Freeman et al. 2003). Furthermore, Sp3 can 
also be modulated by methylation as previously described for Sp1. All these 
mechanisms contribute to make the Sp3 activity dependent on the cellular, 
nuclear, and gene promoter environments.  
 
3.6.2.3 Sp4 
Sp4 was cloned together with Sp3 and share most of the structural 
characteristics of Sp1. The transactivation ability of this protein can be attributed 
to the N-terminal glutamine-rich domain but it presents different properties and 
mechanism of transactivation compared with the other family members. One of 
the basic differences is that Sp4 is unable to act synergically as homo-dimer, but 
it can bind Sp1 and strongly enhance its activatory effect (Hagen, Dennig et al. 
 
40 
 
1995). At difference with Sp1 and Sp3, the expression of Sp4 is restricted to the 
central nervous system, particularly in cerebellum and hippocampus. In addition, 
neurons express higher concentration of Sp4 compared with astrocytes (Mao, 
Yang et al. 2007). 
Sp4 knock-out mice show low rate of survivability and a delayed physical and 
sexual development (Supp, Witte et al. 1996). On the other hand, Sp4 
hypomorphic mice, with an expression reduction of 95-98% compared to the 
wild-type mice, show an enhanced vacuolization of the grey matter in 
hippocampus. As consequence, Sp4 is also involved in spatial learning and 
memory and LTP mechanisms (Zhou, Long et al. 2005; Zhou, Nie et al. 2010). 
In addition, these mice also show a reduction in the expression of the NR1 
subunit of NMDA receptor. Thus, the relationship of Sp4 with this pathway 
suggest that this protein might be important for all brain disorders characterized 
by glutamate miss-regulation, such as bipolar disorders or schizophrenia (Braff, 
Geyer et al. 2001; Pinacho, Saia et al. 2015). Moreover, this protein plays a key 
role in the development of cerebellar granule neurons (CGN) by regulating target 
genes, such as the neurotrophin 3, that exert a crucial activity in the dendritic 
remodelling and the maturation of these cells during the morphogenesis (Ramos, 
Valín et al. 2009). 
Overall, given the limited expression of Sp4 in CNS, and its importance under 
several neurophysiological functions and pathophysiological disorders, it 
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emerges as an interesting TF that deserves further investigation. On the other 
hand, NCX2 isoforms, displays similar aspects of Sp4 that suggest a possible 
correlation between these two proteins. These aspects include: (1) the expression 
limited in both neurons and glia of CNS; (2) participation in neurotransmission; 
(3) participation in long-term learning and memory; (4) participation in 
neurological cerebral ischemia and psychiatric disorders.  
 
3.6.3 Sterol Regulatory Element Binding Protein (SREBP) 
SREBPs are a group of DNA binding protein classified in the superfamily of 
Basic Helix-Loop-Helix Leucine Zipper transcription factors (bHLH-Zip) 
(Bengoechea-Alonso and Ericsson 2007). Furthermore, SREBPs present a 
particular bHLH that differs from the other members of the superfamily in which 
a tyrosine residue is a substitute to an arginine of the classical structure. This 
mutation make SREBP able to bind both Sterol Regulatory Element (SRE) and a 
motif is known as Enhancer Box (E-Box). 
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SREBPs family is basically composed by 2 isoforms, SREBP1 and SREBP2, 
with a restricted number of alternative-spliced forms (Hua 1993). SREBP1 gene 
presents two different transcription starting sites, encoding for SREBP1a and 
SREBP1c isoforms (Hua, Yokoyama et al. 1993). This latter is involved in 
adipogenesis in rodents, for this reason is also known as Adipocyte 
Determination and Differentiation Factor 1 (ADD1) in rodents (Eberlé, Hegarty 
et al. 2004). Beyond SREBP1a and SREBP1c variants, some other alternative 
spliced forms have been characterized, although they show less importance in 
the family (Nohturfft and Zhang 2009). 
Figure 6 Fig6: Cartoon representing the post-tralational steps to activate SREBP: (1) 
SREBP (purple) is anchored to the ER membrane after its synthesis; (2) under appropriate 
stimulus SCAP (blue)  mediates the cleavage by S1P Golgi protease (orange); (3) S2P Golgi 
protease (orange) release the active transcription factor migrating into the nucleus; (4) the active 
form of SREBP binds the target sequence SRE and exerts the regulatory effect on gene 
transcription 
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SREBPs are transmembrane TF localized on the nuclear membrane or on the 
endoplasmic reticulum. The overall structure of the family presents 5 domains: 
C- and N-terminus, DNA-binding site, two transmembrane segments. N-terminal 
region is the transactivation domain, whereas the C-terminal region is able to 
interact with other regulatory proteins. The DNA-binding domain is 
characterized by the bHLH-Zip sequence. The two transmembrane domains are 
connected by a cytoplasmic segment to anchor this protein to nuclear envelope 
or endoplasmic reticulum. Notably, the central part of the protein present two 
cleavage sites that are important for the release of the active form of the 
transcription factor. This activation requires the action of SREBP Cleavage-
Activating Protein (SCAP) that mediates the cleavage by two different proteases, 
S1P and S2P. 
Protein activation is dependent on several conditions, including cholesterol 
and triglyceride levels. In particular, when cholesterol concentrations are 
maintained under physiological levels, SREBP protein remains in an inactive 
form. By contrast, when cholesterol levels drop, SCAP triggers the translocation 
of the SREBP-SCAP complex to the Golgi to obtain the activation by S1P/S2P 
proteases. The released active form of SREBP moves into the nucleus where it 
regulates gene transcription (Fig. 6) (Gasic 1994). 
SREBP is a weak gene activator but its activity is highly enhanced when it 
interacts with co-regulators (Magaña and Osborne 1996). In this regards, SREBP 
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reaches the highest transcriptional activity when the target promoter presents a 
binding sequence for co-regulators that is proximal to at least two consecutive 
SRE element (or SRE/E-box tandem). Most frequently, the co-regulators found 
to interact with SREB are Sp1, and Nuclear Factor Y (NFY). The binding motif 
on the first one must lay on a maximum distance of 10bp from the SRE 
sequence, whereas the NFY can range to 30 bp (Amemiya-Kudo, Shimano et al. 
2000). 
Despite principal SREBP target genes seems to be related to the cholesterol 
and fatty acids biosynthesis, in the last few years, ChiP experiments and RNA 
interference revealed a growing number of genes involved in other cellular 
processes than lipid metabolism, like cell cycle, proliferation and apoptosis 
(Reed, Charos et al. 2008; Rome, Lecomte et al. 2008). In fact, SREBP is highly 
expressed in neuron and glia where it participates in the myelination process 
(Camargo, Smit et al. 2009). In addition, SREBP1c mediates the transcription of 
polyunsaturated fatty acid (PUFA) regulators under pathophysiological 
conditions. In particular, SREBP1c can regulate stearoyl-CoA desaturase 
(SCD1), delta-5 desaturase (D5D) and (delta-6 desaturase D6D) that participate 
to the insulin-dependent control of PUFA metabolism. Abnormal regulation of 
this pathway is involved in neurodegenerative disease, such as Alzheimer’s, in 
several neurological and behavioural disorders (Nakamura and Nara 2004), and 
in glioma (Ru, Hu et al. 2016). Moreover, SREBP translocation and activity are 
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impaired in Huntington’s disease. This effect might be explained by two 
complementary hypothesis: (1) Huntingtin abnormalities may lead to the 
malfunction of the shuttling process (Ossareh‐Nazari, Gwizdek et al. 2001); (2) 
SREBP might be misregulated by post-traslational mechanisms, such as 
SUMOylation, which are altered in Huntington’s disease (Steffan, Agrawal et al. 
2004). 
3.7 Epigenetic Regulation 
Epigenetics controls stably heritable phenotypes that does not result from 
changes in genomic DNA sequence. In fact, despite most of the cells in an 
organism share the same DNA, the expression of several genes might differ over 
the time by histone modification, DNA methylation, RNA interference and 
nucleosome positioning. Thanks to these marks, the regulation of target genes 
can occur without change the sequence of nucleotides. Since the embryogenesis, 
these mechanisms occur over the time and might endure even after cell division 
for the lifetime (Bird 2007). Moreover, environmental stimuli can modify these 
epigenetic mechanisms in the whole organism or in some cell groups (Görisch, 
Wachsmuth et al. 2005). 
Histones are important for epigenetic mechanisms since thy bound the 
genomic DNA and cause chromatin packaging. Modifications of these proteins 
are able to tight or loosen DNA binding, and thus, they participate in the 
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regulation of gene promoter access for TFs. Histone modification involves 
almost 60 residues, most of which are located on the N-terminus tails. 
Modifications includes methylation, acetylation, citrullination, ADP-ribosylation 
phosphorylation, ubiquitination, and SUMOylation (Khorasanizadeh 2004; 
Kouzarides 2007; Christophorou, Castelo-Branco et al. 2014). Histone 
modifications produce different functional outcomes depending on the position 
where they occur along the gene. The number of modification and the modified 
residues are also important for the output effect. It was reported that tri-
methylation of histone H3K4 marks an active gene promoter, whereas single 
methylation on the same residue is characteristic of distal regulatory regions. On 
the other hand, tri-methylation of H3K27 is peculiar of an inactive promoter 
(Bernstein, Meissner et al. 2007; Schneider and Grosschedl 2007). 
Another common signalling tool to control gene expression is the DNA 
methylation. This epigenetic modification occurs at the cytosine base of a CpG, 
which is converted to a 5-methyl-cytosine by a DNA methyltransferases 
(DNMTs) enzyme. CpG residues are globally distributed in the entire genome 
and they are frequently grouped in sequences of 300-1,000 bp, known as CpG 
islands. For many years, methylation of these sequences was typically associated 
with gene silencing, however,  in some cases, methylation plays a role in 
mediating gene expression (Suzuki and Bird 2008). A growing number of 
transcription factor have been found to bind sites that present or not a methylated 
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CpG sequence in the core of the binding site. These factors are able to give 
different output activities depending on the presence the dinucleotide in the 
binding motif. Thus, methylation regulates the interaction of a class of methyl-
binding transcription factors with the DNA (Zhu, Wang et al. 2016). 
Interestingly, several studies are focusing their attention on the alteration of 
these pathways under some pathophysiological conditions. 
All these epigenetic mechanisms are not independent, since they intertwine in 
a dynamic pattern of reaction that outcome to different cellular expression 
profile (Vaissière, Sawan et al. 2008). Condensed chromatin usually presents a 
combination of histone modifications and DNA methylation. It has been 
postulated that these two mechanisms can be influenced each other’s (Nan, Ng et 
al. 1998; Reddington, Perricone et al. 2013). This may occur because DNMTs 
can be recruited by particular histone modification. Otherwise, methyl-CpG 
residues may indicate the locus that must be inactivated by DNA condensation 
(Ooi, Qiu et al. 2007; Cedar and Bergman 2009; Zhao, Rank et al. 2009). One of 
the canonical examples that show the importance of DNA methylation in gene 
expression is the inactivation of chromosome X during development. 
Due to the critical role of epigenetic modifications, an amount of research has 
underlined the connection between dysregulations of these mechanisms and a 
wide range of diseases including lupus, muscular dystrophy, birth defects and 
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cancer. In particular, DNA methylation represents a key tool to suppress genes 
involved in tumor growth (Robertson 2005). 
3.8 Strategies for identifying mammalian regulatory sequences  
The analysis of regulatory motifs in genomic DNA acquires a particular 
relevance to understand the mechanisms that regulate gene expression. In the 
past, experimental determination of the sequences where the TFs bind DNA was 
not practical and efficient. However, the use of new techniques, including new 
generation sequencing, cDNA microarray, and chromatine immunoprecipitation 
(ChiP), offered a chance to discover new binding motifs, and their variants, 
extending the knowledge on the consensus sequence that a TF can bind. 
One of the most common strategies to describe a TFBS is the position weight 
matrix (PWM) which is a probabilistic model that quantifyes the DNA binding 
preference of a TF. A PWM is generally learned from a collection of aligned 
DNA binding sites that come from sequencing techniques. Theoretically, the 
output of collected data can be formulated as a maximum likelihood problem. To 
solve this problem it can be supposed that sequencing of binding sites consist of 
random independent observations from a product multinomial distribution. In 
the distribution of all the reads, each entry is proportional to the observed count 
of its corresponding nucleotide at a corresponding position (Wilson and Chen 
2007).  
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fb,i= counts of base b in position I; N= number of sites; p(b,i)= corrected probability of base b in position I; s(b)= pseudocount function; p(b) 
= background probability of base b; Wb,i = PWM value of base b in position i 
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The first step is to collect a good number of sequencing for the predicted TF 
from novel read, a database or from literature (fig 7a). A way to describe this 
output is a Consensus Sequence Model: a motif based on the IUPAC nucleotide 
symbols for each position. However, as shown in the example reported in figure 
7a and 7b, an output with a high varied sequence can influence the consensus 
output with the same weight of the others sequences, i.e. site 8 present only 50% 
of the conservation compared to the other sites. 
A better way to describe the sequence output is to create a Position Frequency 
Matrix in which is reported the count of all the nucleotides in each position (Fig 
7c). The frequency matrix is usually normalized and converted in a PWM (Fig 
7d) with the following equations:   
In this way, a value can be attributed to each nucleotide of an unknown 
sequence. The sum of the values of all the positions can return as a relative score 
(fig 7e) compared to the score of the PWM (Wasserman and Sandelin 2004). 
The relative score count 1.00 when each position has the maximum value 
reported by the PWM.  
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To date, there is an increasing number of PWMs databases for many TF. 
TRANSFAC® (Matys, Fricke et al. 2003), JASPAR (Vlieghe, Sandelin et al. 
2006) or MATINSPECTOR (Cartharius, Frech et al. 2005) also incorporate 
many internet-based software tools that allow to formulate a complete 
bioinformatic analysis of an unknown sequence. 
These databases provide a strong likelihood for in silico analysis of a TFBS. 
However, some experimental discrepancy between the in vivo and in silico 
results can be observed. These discrepancies indicate that additional factors 
participates to the function of the regulatory sequences. Usually, two additional 
complementary observations regarding the characteristics of a promoter give 
substantial improvements in the prediction of functional binding sites. 
Figure 7 Building models for predicting transcription-factor binding sites: table from 
Wasserman and Sandelin (2004).  (a) Data collected from literature and sequencing, (b) motif 
sequence derived from table a. (c) table displaying positional frequency matrix. (d) position weight 
matrix obtained from table c. (e) site scoring a representative unknown sequence. (f) Sequence logo 
that displays the weight of each nucleotide in the relative position. 
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Firstly, analysis of sequence conservation in the regulatory region can 
enhance the predictive specificity with matrix models. Secondly, cooperative 
interactions between TFs can contribute in gene regulation, and thus they must 
be considered in the computational algorithms to improve performance. 
In this regard, some emerging user-orientated tools combine matrix-based site 
predictions with phylogenetic footprinting. In general, these tools require pairs 
of orthologous gene sequences. A database of PWM binding profiles, such as 
JASPAR, is used to predict binding sites within the conserved regions. This 
methods requires the most stringent parameters to predict TFBSs that are 
conserved among orthologous sequences (Wasserman and Sandelin 2004). 
3.9 Concluding remarks  
All these data suggest that that transcriptional regulation is a complex 
dynamic process. The interplay between the entire suite of core promoters, 
proximal regulatory elements, and distal regulatory elements, as well as their 
binding factors and cofactors contribute to the transcriptional output of a given 
promoter. Regulatory systems are also highly sensitive, since even single-
nucleotide differences can result in a significant different effect on gene 
expression. Current endeavours aiming to annotate all the transcriptional 
regulatory elements in the human genome face considerable challenges. TFBSs 
are small, degenerate, often located distantly from the promoter upon which they 
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act, and are not always conserved through evolution. These properties make 
regulatory elements difficult to identify through computational means alone. 
Many experimental methods show binding of a transcription factor at a given 
site, but do not assess the functional significance of that binding. Functional 
assays that directly assess the regulatory capacity of a site are the best available 
tools, and the current challenge is to adapt these methods for their high-
throughput usage to screen the entire human genome. 
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Chapter 4: Objectives 
 
 
Since NCX2 antiporter exerts an important role under several physiological 
and pathophysiological conditions, the knowledge on its gene regulation might 
contribute to understand the etiopathogenetic of several neudegenerative and 
neurological diseases. In addition, the identification of mechanisms able to 
increase its expression and its activity might characterize new molecular targets 
useful for clinical prognosis and diagnosis, or might open new paths for the 
treatment of those diseases of CNS in which a dysregulation of Na+ and Ca2+ 
homeostasis occurs. 
The identification of the NCX2 promoter will represent the first step to 
understand the molecular determinants that controls its transcription under 
physiological and pathophysiological conditions. 
 
To this main aim, the present thesis was focused to:  
 isolate the promoter of slc8a2 gene encoding for NCX2 
 characterize the minimal promoter of slc8a2 gene encoding for NCX2 
 identify several transcription factors involved in the regulation of 
NCX2 expression in CNS 
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 recognize the molecular determinants for the effect of transcription 
factors on NCX2 promoter 
 find epigenetic mechanisms that might be involved in NCX2 
expression in CNS 
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Chapter 5: Materials and Methods 
 
 
 
5.1 In silico analysis 
Rat intergenic region between kptn and slc8a2 genes was analysed by 
comparing the putative transcription binding sites with those obtained from the 
orthologous region in human and mouse genome. In particular, we obtained the 
putative transcription binding sites for each species by using Genomatrix 
MatInspector (http://www.genomatix.de) and Jaspar (http://jaspar.genereg.net) 
websites with a threshold of 0.80 for both matrix similarity and core similarity 
scores. Afterwards, we selected those binding sites that are conserved among the 
species for the relative position and that present possible cofactors in their 
proximity. 
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5.2 Primer design and synthesis 
In this work, to isolate SLC8A2 promoter we designed primers to amplify 
different regions reported in the following table: 
 
 
Region 
Primer Sequence Amplified Length 
Whole 
intergenic 
Region 
Forward 5’-AGCTATGAAGCCGTTCTCTGCTC-3’ 
5850 
Reverse 5’-GGATGTTGCTCAAAGGCACAGTAC-3’ 
Region S1 
Forward 5’-CATGCAAGCAAGGGAGGTGTC-3’ 
1072 
Reverse 5’-GTGGCTCAGTGGTTGAGCCC-3’ 
Region S2 
Forward 5’-ACACCTTCTGTGGGCTGTATAGCGG-3’ 
1258 
Reverse 5’-GTCTAACCCACAGCCTGCCCT-3’ 
Region S3 
Forward 5’-TCCTTCCTTCCCTACCTTGCC-3’ 
1476 
Reverse 5’-GCCCAGAGACAGACAGACAGACAT-3’ 
Region S4 
Forward 5’-AGCTATGAAGCCGTTCTCTGCTC-3’ 
1146 
Reverse 5’-AGCACTCCTACCTACAAGTGCACAG-3’ 
 
Primers used to amplify candidate promoter regions were designed according 
to the melting temperature reported by Oligo-Calculator analysis tool, version 
3.27 (http://biotools.nubic.northwestern.edu).  
Primers for site-directed mutagenesis were designed with a Tm >78°C 
calculated according to manufacturer protocol (Agilent technologies, Italy). 
Briefly, we used the following formula: 
Tm =81.5 + 0.41(%GC) – (675/N) - % of Mismatch 
where N is the primer length and %GC and % of mismatch are whole numbers. 
Primers were provided from Eurofins Genomics (Munich, Germany) in 
lyophilized form and eluted to obtain a stock concentration of 100 mM stored at  
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-20 °C and thaw in ice before use. See supplementary section for other primer 
sequences used in this work. 
5.3 Polymerase chain reaction 
PrimeSTAR GXL DNA Polymerase (Takara, cod. R050A) was used to obtain 
all PCR products for cloning experiments. According to the manufacturer 
protocol, the reaction mixture and thermocycler protocol used for the 
amplification contained: 
 
Mix  Thermocycler Protocol 
5X PrimeSTAR GLX Buffer 10 µl 98 °C for 10 sec  
 
30 
Cycles 
dNTP Mixture (2.5 mM) 4   µl 60 °C for 30 sec 
Forward primer (10 pmol) 10 µl 68 °C for 1 min/kb of amplicon 
Reverse primer (10 pmol) 10 µl   
DNA Template (100ng/ul) 1   µl   
PrimeSTAR GXL DNA Polymerase 1   µl   
ddH2O 14 µl   
 
5.4 Agarose gel electrophoresis 
Electrophoresis was carried out in 1% agarose gel made in 1x Tris-acetate-
EDTA buffer (40 mM Tris pH 7.6, 20 mM acetic acid, 1 mM EDTA) 
supplemented with ethidium bromide (250 ng/µl). PCR products were loaded on 
the gel with 1kb DNA ladder (Invitrogen) as a marker of molecular weight. 
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DNA was visualised using a UV transilluminator and photographed digitally 
using ChemiDoc™ XRS+ System with Image Lab™ Software (Bio-Rad). 
5.5 DNA cloning in promoterless luciferase reporter vector 
Genomic DNA was cloned in the pSC-b vector by using StrataClone Blunt 
PCR cloning kit (Agilent) by using the manufacturer protocol as illustrated in 
Fig. 8. 
Briefly, PCR products were ligated with the StrataCLONE Blunt Vector Mix 
and added to an aliquot of STrataCLONE SOLO ultracompetent cells. Bacterial 
Figure 8 Schematic representation of insertion of PCR product in pGL3-basic vector. 
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cells were incubated in ice for 30 minutes, treated with a thermic shock (42°C 
for 30 seconds, 2 minutes in ice), resuspended in 300 µl of LB medium and then 
incubated for 1 hour at 37°C to express the antibiotic resistance of the 
internalized vector. Finally, cells were plated on LB-agar plates with ampicillin 
(50 μm/ml) and incubated overnight at 37°C. Single colonies were incubated in 5 
ml of LB medium with ampicillin (50 μg/ml) overnight at 37°C. 
DNA plasmid was extracted from bacteria cultures with PureYield™ Plasmid 
Maxi- and Mini-prep System (Promega, Italy). Positive vectors were identified 
by using enzymatic digestion followed by DNA sequencing (Microgem, Italy). 
pSC-B-promoter and pGL3-Basic plasmids (Promega) were digested with the 
appropriate restriction enzymes. Fragments of the samples were 
electrophoretically separated on an agarose gel and the corresponding bands 
were extracted with StrataPrep DNA Gel Extraction Kit (Agilent) according to 
with the manufacturer protocol. 
Promoter fragments and pGL3 fragment were ligated with T4 ligase enzyme 
and transformed into Subcloning Efficiency™ DH5α™ competent cells 
(Thermofisher, USA). Positive colonies were incubated in 400 ml of LB medium 
and plasmids were extracted from bacterial cells with PureYield™ Plasmid 
Maxi-Prep Kit (Promega) 
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5.6 Restriction Enzyme Digestion 
All vectors were digested with appropriate restriction enzymes (Promega) to 
cut the insert. The recipe for the digestion reaction is shown in the following 
table: 
Restriction Enzyme 1 0,5-2 µl 
Restriction Enzyme 2 0,5-2 µl 
Buffer 10X 5 µl 
BSA 10X 5 µl 
DNA Template 2-5 µg 
H2O Up to 50 µl 
Final Volume  50 µl 
 
The reactions were performed by incubation at 37°C for 1 hour and then 
blocked in ice until loaded in agarose gel. 
5.7 Site-direct Mutagenesis 
All mutagenesis experiments were performed by using QuikChange Lightning 
Site-Direct Mutagenesis Kit (Agilent) according to manufacturing protocol by 
using the following PCR protocol 
1. 95°C for 2 minutes 
2. 95°C for 20 seconds 
3. 60°C for 10 seconds 
4. 68°C for 30 seconds 
5. 68°C for 5 minutes 
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Steps from 2 to 4 were repeated 18 times  
PCR products were incubated with Dpn I restriction enzyme for 5 minutes at 
37°C.  Subsequently, the transformation of Dpn-treated samples was performed 
into 45 ul XL10-Gold bacterial cells according to the above-mentioned protocol.  
 
5.8 Isolation and retrotranscription of RNA  
Total RNA was extracted from cells using TRIzol® (Thermofisher) reagent 
according to Maniatis protocol (Maniatis, Fritsch et al. 1982). Total RNA was 
eluted in 10 µl of nucleases free H2O and 1/10 of the samples was loaded on a 
denaturating agarose gel to control and quantify RNA integrity. Two µg of total 
RNA were treated with DNase I (Sigma) and retrotranscribed by High-Capacity 
cDNA Reverse Transcription Kits (Life Technologies) according to the 
manufacturing protocol. Briefly, the following reaction mix was used to digest 
DNA 
 
 
RNA 2 μg 
DNase I (1 U/μL) 1 μl 
DNase Buffer 10X 1 μl 
H2O up to 10 μl 
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The mix was incubated for 15 minutes at room temperature and then was 
added 1 µl of the Stop Solution. Samples were heated at 70°C for 10 minutes and 
chilled in ice. Retrotranscription was performed by adding 10 μl of RT 2x mix 
and incubated at 25°C for 10 minutes, at 37°C for 2 hours and then at 85°C for 5 
minutes. 
5.9 Real-time PCR  
Quantitative real-time PCR was carried out using 1/20 of the cDNAs with 
Fast SYBR Green60 Master Mix (Applied Biosystems). Samples were amplified 
simultaneously in triplicate in one assay as follows: 2 min @ 50º C, 10 min @ 
95º C, 15 sec @ 95º C;1 min @ 60º C (7500 fast real-time PCR system, Applied 
Biosystems, Italy). 
Steps 3 and 4 were repeated 40 and a single fluorescence measurement was 
obtained each cycle at step 4. qPCR data was collected using ABI Prism 7000 
SDS software (Applied Biosystems). Differences in mRNA content between 
groups were calculated by using HPRT mRNA as the internal control. Data were 
analysed with Pfaffl method (Pfaffl 2001).  
5.10 Cell Lines 
Pheochromocytoma cell line (PC12) was maintained in culture in complete 
RPMI (500 ml RPMI (Invitrogen, Italy) 100 µg/ml penicillin 100 µg/ml 
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streptomycin 4 mM L-glutamine 10% of decomplemented fetal bovine serum, 
5% of horse serum). When confluence reached 80%, cells were washed with 
PBS (0.2 g/l KCl, 8.0 g/l NaCl, 0.2 g/l KH2PO4, 1.44 g/l Na2HPO4, up to 500 ml 
of ddH2O), detached from plates using Versene solution (0.2 mg/ml EDTA 
disodium salt in PBS) and a new sub-colony was established.  
Neuroblastoma SH-SY5Y and Glioblastoma U87-MG cells were maintained 
in culture in complete DMEM medium (500 ml DMEM, 100 µg/ml penicillin, 
100 µg/ml streptomycin, 4 mM L-glutamine. 10% of decomplemented fetal 
bovine serum), washed with PBS and detached from the plate using trypsin-
EDTA solution. 
Baby hamster kidney (BHK) cells were maintained in culture with medium 
containing 250 ml of DMEM, 250 ml of F12, 100 µg/ml penicillin, 100 µg/ml 
streptomycin, 4 mM L-glutamine, 10% of fetal bovine serum; washed with PBS 
and detached using Versene solution.  
All cell lines were incubated in a humidified incubator at 37 ºC and 5 % CO2.  
Cells in their early passage were detached and counted. Then, 2 million cells 
were suspended in 1 ml of freezing solution (90% growth medium, 10% DMSO) 
and put in 1 ml cryogenic vials and stored at -80 ºC. For the thawing procedure, 
cells were rapidly thawed in a water bath at 37 ºC and transferred to a 15 ml tube 
with 7 ml of complete growth media. Then, cells were spun at 1,200 rpm (250 g) 
for 5 min, the media was removed and cells were suspended in the culture plate. 
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5.11 Eukaryotic transfections  
All transfections were performed with Lipofectamine 2000 (Life 
technologies). 
For the luciferase experiments, cells were plated in a 12-well plate at a 
concentration at planting time of 40,000 cells/well. After 24 h, cells were 
transfected with 1 µg of total plasmid DNA and 4 µl of Lipofectamine 2000 
according to manufacturer protocol.  
For the promoter individuation experiments 900 ng and 100 ng of pGL3-
promoter and pRL-TK plasmids were used, respectively. 720 ng of pGL3-
Promoter, 80ng of pRL-TK and 200ng of TF-cDNA expression plasmid were 
used in the analysis of the promoter regulation. 
For the transfection of transcription factor cDNAs, cells were plated in 60 mm 
plate with a concentration of 150,000 cells/plate at plating time and transfected 
with 5 µg of plasmid DNA with 10 µl of Lipofectamine 2000. 
For all the experiments, during transfection cell medium was substituted with 
reduced serum medium Opti-mem (Gibco) for 5 h. Afterwards, cells were 
incubated for 48 h with the culture medium until the experiments.  
5.12 Gene Reporter luciferase Assay 
Luciferase assay was performed with Dual-Luciferase® Reporter Assay 
System (Promega) according to the manufacturer protocol. Cells were collected 
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from the plate using provided lysis buffer, treated with two subsequent frost-
thaw cycles ( -80 °C for 40 minutes, 37 °C for 2 minutes) and centrifuged 
(12,000 g for 20 minutes at 4 °C). Bioluminescence measurement of Pontius 
luciferase was performed with Glomax® 20/20 luminometer by adding LAR 
substrate buffer to a protein sample. Next, Renilla luciferase luminescence was 
measured adding the Stop&GLOW buffer to inhibit Photinus luciferase and 
providing a correct substrate to Renilla luciferase. Photinus luminescence was 
normalized with Renilla luminescence and expressed as “Relative Luciferase 
Activity”. 
5.13 5’-Azacytidine (5-AZA-dC) administration 
U87 cell line was treated once with 1, 5 or 10 µM at 5 h after plating time. 
mRNA was extracted from cells after 24h, 48h, 72h or 96h, and RT-PCR were 
performed using O-6-methylguanine-DNA methyltransferase (MGMT) mRNA 
expression as control (Cairns 2009). Finally, we used a treatment of 5 µM of 
5Aza-dC for 72h in following experiments. 
5.14 DNA bisulfite conversion and sequencing 
In silico prediction of bisulfite-treated DNA sequence was performed with 
Bisulfite Primer Seeker tool (Zymoresearch) and primers were designed to 
amplify PCR products of 200-500bp. Bisulfite reaction was performed using 
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EpiJET Bisulfite Conversion Kit (Thermofisher Scientific) according to the 
manufacturer protocol. Converted genomic DNA was amplified by PCR reaction 
using Hot Start Taq DNA polymerase (Thermo Scientific). PCR products were 
electrophoretically separated on 1% agarose gel. Bands were extracted from the 
gel, purified and singly cloned in the pSC-B vector as described previously. 
pSC-B-fragment vectors were sequenced by Microgem s.r.l. (Naples, Italy)  
5.16 Statistical Analysis  
Data are expressed as mean (S.E.M.). Statistical comparisons between control 
and treated experimental groups were performed using the one-way analysis of 
variance, followed by Turkey test. Statistical comparisons of methylation 
between two cell lines were performed using χ2 test. All tests were performed 
using GraphPad Prism (GraphPad Software, USA) and considered statistically 
significant with p<0.05. 
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Chapter 6: Results 
6.1 Overview of the gene locus  
Isoform 2 of sodium/calcium exchanger is encoded by Slc8a2 gene. The locus 
in which NCX2 gene is located is highly conserved among different species. It 
includes five genes, Napa, Kptn, Slc8a2, Meis3, and Dhx3, with the same 
position and orientation in different mammal species (Fig. 9A). 
We designed and analyzed the whole intergenic region and four smaller 
subregions to investigate the presence of cis-acting elements which localization 
can indicate a core promoter sequence between Kptn and Slc8A2 genes. In 
addition, we compared our finding with the analysis of orthologous sequences in 
human and mouse DNA. Sequences alignment among these three species 
revealed that human exon 1 consist of a 379 bp sequence whereas, rat and mouse 
exon sequences are shorter (91 bp and 74 bp respectively) but highly conserved 
if compared to human sequence. In silico analysis revelaed the presence of two 
highly predictive initiator motifs. The first is located at the 5’ end of the rat and 
mouse exon 1, whereas the second is located ~300 bp upstream of the first one. 
In addition, the second motif is located in a region of rat and mouse DNA 
corresponding to the beginning of exon 1 in human orthologous sequence (Fig. 
9B). 
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Figure 9 Relative position of the neighbour genes of NCX2 and putative promoter 
alignment: (A) Schematic representation of Slc8a2 locus conserved in several mammals and 
lower species. (B) Schematic representation display the promoter features of Slc8a2 5’UTR 
region in human, rat and mouse. White boxes represent exon alignment, blue boxes represent 
CpG island and in green were displayed the Inr motifs conserved in all the tree sequences. 
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We found that 80% of the predicted GC-boxes are localized in the region 
upstream the exon 1. In rat, these motifs grouped in two CpG island, one of 364 
nucleotides with a CG content of 61% and a second most dense island of 627 
nucleotides with a CG content of 66% localized upstream the identified Inr 
(Supplementary Table S2, S3, S4).  
6.2 Determination of Core Promoter Activity 
All promoter constructs, including the intergenic region between kptn and 
slc8a2 genes (-1929/+3912 bp), and its subregions S1(+2957/+3912 bp), S2 
(+1295/2560 bp), S3(-709/+595 bp) and S4(-1929/-850 bp), were singly 
transfected in PC12 cells and bioluminescence was evaluated 48 h later. In all 
experiments, a pRL-TK vector carrying Renilla luciferase was cotransfected and 
used as internal control to normalize transfection efficiency and cell number 
variability. In addition, a reporter vector containing the Simian virus 40 (SV40) 
promoter (pI-S0) was used as positive control, whereas the promoterless empty 
vector pGL3-Basic was used as negative control to detect the background 
expression level of the luciferase reporter assay. Promoter activity for all 
constructs was expressed as arbitrary units. 
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Figure 10 Identification of NCX2 promoter: (A) Schematic representation of the intergenic 
region between Kptn and Slc8a2 genes in rattus norvegicus genome. S1, S2, S3, and S4 
subregions are represented in cyan. (B) Transcriptional activity of several promoter regions of 
slc8a2 gene  measured as bioluminescence in pGL3basic plasmid. *, p<0.05 vs background 
signal (empty vector); **, p<0.05 vs S3 group. 
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Transfection of the luciferase constructs carrying the whole intergenic 
sequence (-1929/+3912), the subregions S1(+2957/+3912), S2(+1295/+2560) 
and S4(-1929/-850) displayed a weak transcriptional activity, whereas the 
construct including S3(-709/+595) sequence as promoter displayed a significant 
luciferase activity (Fig. 10B). 
6.3 Comparison of promoter activities in several species 
The promoter activity of the region S3(-709/+595) was investigated in several 
rodents and human cell lines expressing or not expressing the endogenous 
NCX2. In particular, both PC12 and SHSY cell lines showed a marked amount 
of NCX2 mRNA normalized for HPRT expression, whereas BHK and U87 cells 
did not show a significant signal of NCX2 mRNA as compared to the 
background signal (Fig. 11A). The transfection of pGL3-S3(-709/+595) showed 
a significant increase in luciferase activity as compared with the empty vector 
pGL3-basic in both cell lines expressing NCX2, PC12 and SHSY (Fig. 11B). On 
the other hand, transfection of pGL3-S3(-709/+595) did not show significant 
increase in luciferase activity in both cell lines that do not express the 
endogenous NCX2, BHK and U87 (Fig 11B). In addition, transfection of 
constructs including S3 subregions in both PC12 and SHSY cells showed an 
increase in luciferase activity from the whole S3 sequence until the subregion 
S3(+113/+595) (Fig 12). By contrast, the transfection of the plasmid carrying the 
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subregion +424/+595 of S3 dropped the transcriptional enhancement in both cell 
lines (Fig 12).  
 
Figure 11  Activity of NCX2 promoter in several cell lines: (A) level of mRNA expression of NCX2 in 
several rodent and human cell lines. Data are normalized by HPRT expression level. (B) Enhancer activity of 
region S3 in cells expressing or not expressing NCX2. Data are reported luciferase activity in arbitrary units. *, 
p<0.05 vs respective empty pGL3basic control group. 
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Figure 12 Luciferase activity of NCX2 promoter subregions in PC12 and SHSY cell lines: 
Subregion of NCX2 were transfected in PC12 (A) and in SHSY cell lines (B). *, p<0.05 vs 
pGL3basic group; **, p<0.05 vs S3 group, ***, p<0.05 vs S31 and S33 groups. 
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6.4 Analysis of cis-acting regulatory elements of S3 region 
In silico analysis of rat S3 region revealed 788 putative transcription factor 
binding sequences with a threshold score above 80% (supplementary table 5) 
and 40 putative CpG methylation sites. In addition, these binding sites of rat S3 
were compared with those obtained in the ortholog regions of mouse and human 
genome looking for conserved consensus sequences. In addition, we also 
considered the relative position of the consensus sequences from the 
transcription start site as a filter (supplementary table 5). 
Epigenetic analysis revealed that both CpG islands of S3 region are 
methylated under control conditions in the PC12 cell line. In addition, these CpG 
islands were also found methylated in L6 cell line that does not express NCX2. 
However, the frequency of methylation was higher on CpG sites 4, 5, 29 and 33, 
and was lower on CpG sites 1, 23, 24 and 25, in PC12 cells as compared with L6 
cells (Fig. 13B) 
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Figure 13. NCX2 promoter sequence and methylation status: (A) S3 sequence of rat slc8a2
gene with several conserved consensus sequences for the transcription factors Sp1/3/4, GATA1/2, 
RUNX1, SREBP1, NFkB, CREB and the transcription initiator sequence Inr. Numbers in black 
circles indicate putative methylation sites. TSS is for transcription starting site. (B) Methylation 
status of CpG sites in PC12 and L6 cells, expressing and non-expressing NCX2, respectively. 
Numbers indicate the relative site in the sequence of panel A. Black-filled circle indicates 
methylated sites, open circle indicates not-methylated sites. *, p<0.05 vs respective site in PC12 
cells 
 
 
76 
 
6.5 Effects of several transcription factors on NCX2 putative promoter 
Selected transcription factors were selected to assess their effects on the 
transcriptional activity of the identified promoter region of NCX2. In particular, 
we selected several transcription factors on the basis of: 
 The presence of almost one putative binding site on the promoter 
region with a high identity score on the known matrix (MatInspector, 
Jasper).  
 The presence of almost one putative binding site conserved among the 
three considered species, rat, mouse, and human  
 The expression in CNS 
Results showed at least 9 transcription factor that might regulate the activity 
of the identified promoter of NCX2. Among these, the transfection of CREB1a, 
Sp1, or Sp4 enhanced the bioluminescence activity of pGL3-S3 in PC12 cells, 
whereas SREBP1 transfection abolished the luciferase activity of pGL3-S3 in 
same cells (Fig 14). On the other hand, the transfection of Sp3, RUNX1, 
Gata1/2, or NFkB1, although possess one or more putative conserved binding 
sites, did not show significant regulation of the identified promoter under our 
control conditions as compared with the empty vector of the transcription factors 
(Fig.14). 
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Figure 14 Effect of transcription factors on the identified promoter of NCX2: pGL3-S3 was 
cotransfected with single transcription factor in PC12 cell line. Luciferase activity was expressed as 
arbitrary units and normalized for the basal activity of pGL3-S3+mock. On the left, there is a 
representation of positions of binding sites (black box) for the transcription factor transfected. *, 
p<0.05 vs pGL3-S3+mock control group 
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6.6 CREB binding sites 
The putative promoter of NCX2 cloned in pGL3 vector, presented one 
conserved binding site in the region A (-709/-319). The transfection of CREB1a 
increased more than 4 folds the bioluminescence activity of pGL3-S3 in PC12 
cells under control conditions as compared with the transfection of empty vector. 
However, the transfection CREB1 did not affect the luciferase activity of the 
deletion-mutated pGL3-S3(-319/+595) and the deletion-mutated pGL3-
S3(+113/+595), two deletion mutants that lack the region A or both A and B, 
respectively (Fig. 15). 
Figure 15. Activity of CREB on the identified promoter of NCX2: CREB presents one 
conserved putative binding site (black box). Luciferase activity was measured in PC12 cells and 
expressed as arbitrary units and normalized for the basal activity of the respective pGL3-S3+mock 
group. *, p<0.05 vs respective pGL3-S3+mock control group 
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6.7 Sp1 binding sites  
Putative Sp1 binding sites are spread along the whole S3 promoter. In 
particular, one binding site is located in the region A, whereas 12 and 13 binding 
sites were located in the region B and C, respectively. Region D contains the last 
5 conserved putative binding sites identified by in silico analysis. 
The transfection of Sp1 increased 2 folds the bioluminescence activity of 
pGL3-S3 in PC12 cells under control conditions as compared with the 
cotransfection of pGL3-S3b and the empty vector of transcription factors 
(mock). The removal, by site-directed mutagenesis, of the region A or both A 
and B in pGL3-S3 construct did not affect the stimulatory activity of Sp1. By 
contrast, the removal of a wider region, that includes A, B and C, prevented the 
Sp1-mediated enhancement under same conditions. Furthermore, the disruption 
of the Sp1 site at +403 bp in pGL3-S3(+113/+595), which present the highest 
score in the region C, prevented the stimulatory effect exerted by Sp1 on the 
promoter (Fig 16). By contrast, the disruption of the second most probable Sp1 
binding site at +319 bp in pGL3-S3(+113/+595), did not hamper the stimulatory 
effect of the transcriptional factor in PC12 cells under control conditions (Fig. 
16). 
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Figure 16 Activity of Sp1 on the identified promoter of NCX2: Sp1 presents several conserved 
putative binding sites on S3 (black box). Grey boxes indicate the disrupted binding sites in S3 
promoter. Luciferase activity was measured in PC12 cells and expressed as arbitrary units and 
normalized for the basal activity of the respective pGL3-S3+mock group. *, p<0.05 vs respective 
pGL3-S3+mock control group 
 
81 
 
6.8 Sp4 binding sites  
S3 region displayed 3 conserved binding sites for Sp4 located in the region B, 
C and D. Sp4 transfection increased 2 folds the transcriptional activity of pGL3-
S3 in PC12 cells under control conditions as measured by luciferase assay. The 
removal, by site-directed mutagenesis, of either region A S3(-319/+595), or 
both A and B S3(+113/+595), in pGL3-S3 construct did not prevent the 
stimulatory activity of Sp4. By contrast, the removal of either region ranging 
from +376 to +465 in the deletion mutant pGL3-S3(-319/+595) or region 
ranging from +322 to +423 of the deletion mutant pGL3-S3(+113/+595), 
prevented the Sp4-mediated enhancement under same conditions. Furthermore, 
the disruption of the site at +403 bp of pGL3-S3(+113/+595), which presented 
the highest score in the region C, prevented the stimulatory effect mediated by 
Sp4 transfection (Fig. 17).  
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Figure 17 Activity of Sp4 on the identified promoter of NCX2: Sp4 presents three putative 
binding sites on S3 (black box). Grey boxes indicate the deleted sequences or the disrupted 
binding site for Sp4 in S3 promoter. Luciferase activity was measured in PC12 cells and 
expressed as arbitrary units and normalized for the basal activity of the respective pGL3-
S3+mock group. *, p<0.05 vs respective pGL3-S3+mock control group. 
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6.9 SREBP binding sites  
The putative promoter of NCX2 showed 6 conserved binding sites for 
SREBF1 transcription factor, 3 in the region A, 1 in the region B, and 2 in the 
region C. Transfection of SREBP1 markedly decreased the luciferase activity of 
both promoters, the entire S3 sequence and its deletion mutant pGL3-
S3(+113/+595) (Fig. 18). This latter mutant lacks a region including A and B. 
On the other hand, SREBP-1 transfection failed to downregulate the 
bioluminescence of the deletion mutant pGL3-S3(+424/+595) construct under 
the same experimental conditions. In addition, the removal of a region from 
+322 to +423 of pGL3-S3(+113/+595), containing one of the two conserved 
SREBP1 binding sites, did not prevent the downregulation by the transfection of 
the relative transcription factor. 
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Figure 18 Activity of SREBP1 on the identified promoter of NCX2: SREBP1 present six 
putative binding sites on S3 (black box). Grey boxes indicate the deleted sequences or the 
disrupted binding site for Sp4 in S3 promoter. Red boxes indicate Sp1/4 binding sites that can 
represent putative co-regulators of SREBP1. Luciferase activity was measured in PC12 cells 
and expressed as arbitrary units and normalized for the basal activity of the respective pGL3-
S3+mock group. *, p<0.05 vs respective pGL3-S3+mock control group. 
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Figure 19 Ortholog sequences of mouse (in A) and human (in B) of the identified rat S3 
region. several conserved consensus sequences for the transcription factors Sp1/3/4, GATA1/2, 
RUNX1, SREBP1, NFkB, CREB and the transcription initiator sequence Inr are showed in both 
sequences. TSS is for transcription starting site.  
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6.10 Role of Methylation in NCX2 expression 
The effects of CREB1, Sp1 and Sp4 transfection on the transcription activity 
of the identified NCX2 promoter was also evaluated in U87 cells that do not 
express this exchanger under control conditions. The transfection of each above-
mentioned transcription factors failed to induce a significant luciferase activity 
of rat pGL3-S3 in U87 cell line under control conditions (Fig. 20A). On the 
other hand, 72h and 96h of 5 µM 5’-Azacytidine, which prevents CpG 
methylation, induced a transcription of NCX2 mRNA in U87 cell line as 
measured by real-time PCR (Fig. 20B). 
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Figure 20. (A) Effect of CREB, Sp1, Sp4 on the identified promoter of NCX2. Luciferase 
activity was measured in U87 cells and expressed as arbitrary units and normalized for the basal 
activity of the respective pGL3-S3+mock group.  
(B) Effect of 5-Azacytidine (AZA) on NCX2 mRNA levels. NCX2 mRNA was measured by 
real-time PCR in U87 and SH-SY5Y cells, normalized for hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) signals, and expressed percentage of SHSY5Y values. *, 
p<0.05 vs U87+vehicle group 
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6.11 Summary of Results 
These results showed that 4 transcriptional factors, expressed in CNS, are able 
to regulate the transcriptional activity of the identified NCX2 promoter under 
control conditions in cells that express the endogenous NCX2 gene. By contrast, 
these TFs failed to regulate the promoter activity of the identified S3 region in 
cells that do not express the endogenous gene of the exchanger. In particular, 
three TF increased significantly the luciferase activity of pGL-S3 with molecular 
determinants located in the regions A or C. In addition, the binding sequences 
for these TF were also studied. In particular, the molecular determinant for 
CREB1 activity was localized in the region A, possibly at -654 bp from the TSS, 
whereas Sp1 and Sp4 required the binding site at +403 bp, localized in the region 
C. SREBP1 was the only TF that showed an inhibitory effect on the luciferase 
activity. This effect was exerted in all deletion mutants of pGL3-S3 that contains 
region C. In addition, treatment with AZA, which prevents DNA methylation, 
reduced NCX2 silencing occurring in U87 cell line.  
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Chapter 7: Discussion 
 
In this study, we reported the isolation and characterization of the promoter of 
rat NCX2 gene and the molecular determinants involved in the regulation of its 
expression in PC12 cells.  
Results obtained in this thesis showed for the first time a regulatory region 
localized between kptn and slc8a2 genes that is involved in the expression of 
NCX2 in CNS. In particular, this promoter sequence, that we named S3, was 
provided with two high identity matrix scores, above 0.80, of the initiator motif 
that facilitate the transcription by the RNA polymerase complex. These data 
were reinforced by 5’ UTR sequences of mouse and human mRNA encoding for 
NCX2 reported in NCBI database. Indeed, both 5’UTR sequences of mouse and 
human mRNA overlapped with the DNA sequences downstream the observed 
Inr signals. Interestingly, these consensus sequences appeared conserved in rat 
genome where the 5’-UTR sequence of NCX2 mRNA was not reported yet. In 
this regard, from the orthologous comparison and from in silico analysis, it is 
conceivable to hypothesize that the two Inr sequences identified in rat slc8a2 
promoter might represent the effective transcription starting sites of this gene.  
Notably, the identified promoter sequence lacks high predictive TATA-box, 
DPE, and MTE motifs in accordance with the mutually exclusive presence of 
TATA-box and Inr motif, as often sperimentally observed. These data, togheter 
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with the localization of the identified Inr motifs in high-dense CpG islands and 
the presence of many Sp1 binding sites, suggest that the promoter of NCX2 can 
be classified as dispersed (Juven-Gershon and Kadonaga 2010). 
Regarding the intergenic regions surrounding the identified S3 sequence, 
bioinformatic analysis reported a great number of putative TF binding sites 
divided in four dense groups along the entire intergenic region. However, only 
region S3 appeared to promote a significant transcriptional luciferase activity 
under basal conditions even if compared with the promoter activity of the viral 
SV40 sequence. These data suggest that S3 was provieded with the most 
important transcription factors that maintain the basal expresison levels of NCX2 
in the neuronal cell line PC12. In particular, among the 4 identified subregions of 
S3, A, B, C, and D, the basal expression levels of the transcriptional activity 
seemed to be related only to the presence of the subregion C. Indeed, deletion 
mutant that lacks the subregions A, B and C of S3 displayed a low trascriptional 
activity although the reduced length of the sequence. By contrast, the deletion 
mutant lacking A and B showed the highest luciferase activity among S3 and all 
its deletion mutans as observed in both PC12 and SHSY cell lines. These data 
suggested that the subregion of S3 including C and D might represent the 
minimal promoter sequence of NCX2. Indeed, deletion of the subregion A 
enahced, rather than inhibited, the basal transcription activity of S3 promoter in 
both neuronal cell lines, PC12 and SHSY. This might be explained by the 
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presence of binding sites for inhibitory transcription factors that we did not 
examine in this thesis (see supplementart table 5). On the other hand, the 
subregion B was ininfluent for the promoter activity of S3 in SHSY cell lines 
since the S3 mutants lacking the subregion A or both A and B showed the same 
luciferase activity. At difference with these data, the deletion of both subregions 
A and B increased the luciferase activity if compared with the activity of the 
deletion mutant lacking the subregion A in PC12 cells. This discrepancy might 
be partially explained by the difference in the expression levels of several 
transcription factors that substain the basal trascriptional activity of S3 promoter. 
In this regard, it is possible to hypothesize that PC12, but not SHSY, cells 
express inhibitory trascription factors with  molecular determinants present in 
the subregion B. Supporting this hypothesis, SHSY cell line displays an 
increased amount of NCX2 mRNA compared with PC12 cells, as revealed by 
real-time PCR. Regarding the subregion D, we should consider that it showed a 
significant transcriptional activity that might be induced by the presence of 
several binding sites for transcriptional factors with high identity matrix scores 
that we did not exanimed in this thesis. On the other hand, this subregion did not 
contain the molecular determinants for the effect of the transcription factors that 
we used. By contrast, subregion C was the most interesting because it contained 
the regulatory binding sites of Sp1, Sp4 and SREBP1 transcription factors even 
under control conditions. Indeed, Sp1 failed to enhance the promoter activity of 
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NCX2 when region C was removed from S3 promoter. Furthermore, site-
directed mutagenesis showed that the binding site in position +403/+413, 
localized in the region C, is the specific molecular determinant for the Sp1-
mediated enhanced promoter activity in PC12 cells under control conditions. 
Likewise, the neuronal transcription factor Sp4 failed to enhance NCX2 
promoter activity either when the region +376/+465 or +322/+423 were removed 
from S3. Also the disruption of the binding site in position +403/+413, by site-
directed mutagenesis, prevented the Sp4-mediated stimulatory effect suggesting 
that this sequence is crucial for both transcription factors. Notably, this 
transcription binding site showed one of the highest matrix identity score in the 
whole S3 sequence. Interestingly, this subregion was also foundamental for the 
SREBP1-mediated downregulation of NCX2 promoter activity, since the 
removal of the region including A, B and C, but not the removal of the region 
including only A and B, prevented the SREBP1-mediated downregulation of 
NCX2 promoter activity. In fact, two putative SREBP1 binding sites were 
identified in this subregion. It was coinceivable to hypothesize that the sequence 
+388/+398 could represent the molecular determinant for SREBP1 since it was 
provided with a high matrix identity score and was in close proximity to two 
binding sites of its coregulator Sp1. Furthermore, one of these binding sites for 
coregulators was determinant for the effect of both Sp1 and Sp4 on S3 promoter. 
However, the disruption of either Sp1 binding sites or the deletion of a region 
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from +376 to +465 including the three sequences failed to prevent the SREBP1-
inhibitory effect, suggesting that the most probable molecular determinant for 
SREBP1 is located in position +277/+287 in the subregion C. At difference with 
the above mentioned trascription factors, CREB1 showed to exert its activity 
only on the enteire S3 promoter, whereas the deletion of either region A, or both 
A and B, prevented its stimulatory effect on the identified NCX2 promoter. 
These data suggested that the molecular determinant for CREB1 is located in 
position -627/-615 in subregion A. 
Interestingly, the overexpression of either Sp3, NFkB, GATA1/2, RUNX1 
transcription factors failed to modify the promoter activity of NCX2 in PC12 
cells under our experimental conditions, neverthless the promoter was provided 
with their conserved binding sites with high matrix identity scores. On the other 
hand, we can not exclude that these trascription factors might regulate NCX2 
transcription under particular physiological or pathophysiological conditions that 
we did not exanimed. In addition, we also can not exclude that other 
transcription factors that have a conserved binding site on S3 can also partecipate 
in the regulation of the transcription of NCX2. 
Another aspect that deserves attention is the reliability of S3 region as the 
promoter of NCX2. Indeed, we found many putative trascription binding sites 
that were conserved among three considered species, including rat, mouse and 
human DNA. In addition, it is worth of mention that the basal transcriptional 
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activity S3 was comparable with the level of expression of the endogenous 
NCX2 gene in neuronal and non-neutonal cells, including PC12, SHSY, U87, 
and BHK cell lines. On the other hand, the transfection of either Sp1, Sp4 and 
CREB1 failed to induce the transcription of S3 in U87 cell line. These data 
might be explained by several mechanisms of NCX2 silencing. In particular, it is 
known that glioblastoma cells, including U87, show an increase of SREBP1 (Ru, 
Hu et al. 2016) that exerted an inhibitory effect on NCX2 expression. In 
addition, glioblastoma cells show an increase in the methylation of NCX2 gene 
(Qu, Jiao et al. 2010). These aspects appear more interesting if we examine the 
effect of the demethylating agent Aza on the expression of NCX2 in U87 cell 
lines. Indeed, 72h of Aza induced the expression of NCX2 mRNA in U87 cells 
suggesting that the DNA methylation, occuring in glioblastoma, is involved in 
the silencing of this antiporter gene. Furthermore, several putative binding sites 
present on S3 sequence displayed methylable CpG dinuleotides that might 
interfere with the efficacy of the respective trascription factor to modify NCX2 
expression. In this regards, rat myoblast cells that do not express the endogenous 
NCX2 gene showed at least significant difference in 8 CpG methylation if 
compared with rat pheocromocytoma cells. 
Collectively, results obtained suggest that the region S3 represents the 
promoter of NCX2 gene. This promoter is enhanced by CREB1, Sp1, and Sp4, 
whereas it is inhibited by SREBP1 transcription factor in PC12 cells under 
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control conditions. Moreover, our findings also suggested that the epigenetic 
DNA methylation may be involved in the silencing of NCX2 in some cell lines, 
including glioblastoma and myoblastoma cells. 
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Chapter 8: Supplementary Materials 
S-1: Analysis of CpG islands in rat NCX2 promoter sequence 
 
 
 
 
 
 
 
 
S-2: Analysis of CpG islands of mouse NCX2 promoter sequence 
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S-3: Analysis of CpG islands of human NCX2 promoter sequence 
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S-4: List of selected transcription factors binding sites.  
TF RAT MOUSE HUMAN 
 Sequence Pos Score Sequence Pos Score Sequence Pos Score 
CREB1 tgaagcca -627 83% tgaagcca -615 83% ggaggcca -670 80% 
SREBF1 gccacgccaa -532 76% gccacgccaa -523 76% accacgccag -567 82% 
SP3 gcccctgccac -527 80% gcccctgccac -518 80% gccaccaccac -562 82% 
SP1 ccactgcccct -522 82% cctctgcccct -513 87% tgcccgccacc -557 84% 
SREBF1 agcaccttac -461 76% agcaccttac -452 76% ctcaagcaat -508 76% 
SREBF1 cttcccccac -403 76% cttcccccac -393 76% gtcacccagg -448 76% 
RUNX1 tcctgtagttt -288 83% tgctgtggtat -278 91% agctgttgtta -360 82% 
SP3 gccaagcccct -187 87% gccaagcccct -178 87% aagacacccat -340 81% 
RUNX1 gctagtgggtg -172 80% gctagtgggtg -163 80% gtttctggcct -322 84% 
SREBF1 cacgccccat -152 76% gtcacgcctc -71 76% ctgactccag -271 75% 
SP1 gctcctccctc -137 94% gctcctccctc -128 94% tgccctccccc -250 93% 
SP3 gctcctccctc -137 80% gctcctccctc -128 80% tgccctccccc -250 82% 
SP3 gccccgccccc -92 97% gccccgcccct -83 94% cacacacacac -158 83% 
SP4 ctggccacgcctcctcc -75 92% ctggtcacgcctcctca -74 84% cagcccccgccccccaa -145 86% 
SP1 gccacgcctcc -72 87% gtcacgcctcc -71 85% cccccgccccc -142 98% 
SP3 gccacgcctcc -72 96% gtcacgcctcc -71 89% cccccgccccc -142 96% 
SP1 acgcctcctcc -69 84% acgcctcctca -68 80% gcccccgcccc -141 80% 
SP1 ctcgctccctc -13 82% ctcactccctc -13 82% tcccctgcctc -94 84% 
SP1 ctccctcccat -9 91% ctccctcccat -9 91% cccctgcctct -93 87% 
SP3 ctccctcccat -9 83% ctccctcccat -9 83% cccctgcctct -93 80% 
SP1 agccctgccct 3 80% accctaccctc 4 84% ccccagcctcc -70 86% 
SP3 gccctgccctc 4 83% accctaccctc 4 80% ccccagcctcc -70 82% 
SP1 gctcctccctc 20 94% gctcctctttt 20 80% cctcctcccca -64 92% 
SP1 attcctcctcc 49 90% atccctcctcc 45 92% gggcctccccc -21 85% 
SP1 cctcctcctgg 52 80% cctcctcctgg 48 80% cccccgcctcc -14 96% 
SP1 tctcttccttc 97 82% tctcctccttc 93 90% tgcccgcctcc 13 92% 
SP1 gctcctccctc 109 94% actcctccctc 105 91% cctcctccccc 25 95% 
SP3 gctcctccctc 109 80% actcctccctc 105 79% cctcctccccc 25 84% 
SP1 ctccctcttcc 113 82% ctccctcttcc 109 82% cctccccctct 28 83% 
SP1 acaccaccctt 163 83% acaccaccctg 162 81% gctcctccccc 44 97% 
SP1 acccttcctaa 168 79% accctgcctaa 167 80% cctccccctcc 47 84% 
GATA2 aatttcctctctcc 178 80% aatttcctctctcc 177 80% tcaggcttttctct 161 82% 
SP1 tttcctctctc 180 80% tttcctctctc 179 80% ctcgctccctc 58 82% 
GATA1 ttcctctctcc 181 80% ttcctctctcc 180 80% ggcttttctct 164 83% 
SP1 ctctctcccac 184 81% ctctctcccac 183 81% ctccctcgccg 62 81% 
SP1 ctcccacctcc 188 92% ctcccacctcc 187 92% tcgccgcctcc 67 86% 
SP3 ctcccacctcc 188 83% ctcccacctcc 187 83% tcgccgcctcc 67 80% 
SP1 gtcccaccccc 224 96% gtcccaccccc 223 96% ctccctcccct 126 94% 
SP3 gtcccaccccc 224 88% gtcccaccccc 223 88% ctccctcccct 126 84% 
SP1 ccccctctcat 230 82% ccccctcccgt 229 86% tcccctcctcc 131 95% 
SP1 ctccctccttc 250 90% ctccctccttc 249 90% cgcccaccact 207 81% 
SREBF1 atcagccggg 277 76% atcagccgtt 275 79% gccagcccag 218 78% 
NFKB1 gggggaatcagcc 280 82% gggggaatcagcc 278 82% tggggtaaccccg 306 79% 
SP1 cccccgcccca 288 95% cccccgcccca 286 95% cctcctccccg 134 92% 
SP1 cccccggcttc 321 83% cccccggcctc 319 85% actccgcccga 196 81% 
SREBF1 ctcagccccc 388 81% ctcccccctt 391 76% gagaccccat 266 76% 
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S-5: List of conserved putative binding sites for transcription factors 
among rat, mouse and human promoter of NCX2 
 RAT MOUSE HUMAN 
TF Sequence Pos Score Sequence Pos Score Sequence Pos Score 
OTX2  gtgatctt -698 79% gtgatctt -682 79% ttaagccc -789 92% 
FOXC1  aggatcaagat -695 80% aggatcaagat -679 80% aaaaaaaatga -735 82% 
FOXD2  atcaaga -694 81% atcaaga -678 81% gaaaaaa -721 79% 
FOXO4  atcaaga -694 79% atcaaga -678 79% gaaaaaa -721 80% 
PITX3  cttgatcct -693 86% cttgatcct -677 86% aaaaagcct -718 79% 
OTX1  ttgatcct -692 85% ttgatcct -676 85% aaaagcct -717 81% 
OTX2  ttgatcct -692 88% ttgatcct -676 88% aaaagcct -717 81% 
NFIX  cttgccagc -673 96% cgagccaag -657 96% cacgccagg -712 92% 
HES1  accacatgct -651 83% agcatgcggt -639 79% ggcacctgta -694 82% 
NEUROD accacatgct -651 93% accgcatgct -639 89% ggcacctgta -694 82% 
TCFL5  accacatgct -651 85% accgcatgct -639 85% ctcccgagta -676 81% 
TCFL5  agcatgtggt -651 85% agcatgcggt -639 85% tactcgggag -676 81% 
NFIX  gaagccaca -626 84% gaagccaca -614 84% gaggccaag -669 93% 
NFIC  gtggct -624 81% gtggct -612 81% ttggcc -667 94% 
ID4  agcaactgtg -621 82% agcaactgtg -609 82% aactcctggg -642 80% 
SNAI2  cacagttgc -621 81% cacagttgc -609 81% ggctggtct -630 81% 
TCF3  cacagttgct -621 81% cacagttgct -609 81% aactcctggg -642 86% 
TCF4  cacagttgct -621 81% cacagttgct -609 81% aactcctggg -642 84% 
BHLHA gcaactgt -620 82% gcaactgt -608 82% ccttctgc -660 81% 
RFX1  agttgctg -618 85% agttgctg -606 85% tgttaccc -620 83% 
JUN ggaaactgagacag -613 86% ggaaactgaggca -601 82% catggtgagatccc -614 81% 
XBP1  ttcgaag -595 97% ctcgtaa -585 80% ctcaagc -649 79% 
TEAD3  acatttcg -592 84% acattacg -576 84% agatccca -607 79% 
CEBPB  atgttaaaat -588 80% attttgacat -579 81% cccatctcctaaaa -603 81% 
SP4 ctgtccccgccccctcc 407 89% ctgtccccgccccctcc 405 89% tttcccacgcccccacc 285 86% 
SP1 tccccgccccc 410 98% tccccgccccc 408 98% cccacgccccc 288 88% 
SP3 tccccgccccc 410 94% tccccgccccc 408 94% cccacgccccc 288 100% 
SP1 gccccctcccc 415 80% gccccctcccc 413 80% ttcccacgccc 290 83% 
SP4 tggactccgccctcctc 426 79% tgggctccgccctcctc 424 82% gtaaccccgtccttttc 298 80% 
SP1 actccgccctc 429 92% gctccgccctc 427 95% accccgtcctt 301 82% 
SP1 ctcccagcccc 440 83% ctcccggcccc 438 86% actccgcacct 318 83% 
SP3 tcccagcccct 441 81% tcccggcccct 439 80% cccactccgca 321 81% 
SP1 gcccctcccca 446 95% gccccttcccg 444 85% cccccactccg 323 82% 
SP1 tcccctcctag 459 89% tcccctcctcg 457 92% gaaccgccccc 329 83% 
SP3 tcccctcctag 459 80% tcccctcctcg 457 80% gaaccgccccc 329 87% 
SP1 ttccctcctcc 481 93% ctccctcctcc 479 93% cccccacctcc 376 94% 
SP3 ttccctcctcc 481 79% ctccctcctcc 479 82% cccccacctcc 376 90% 
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BARHL1 ttaaaatgga -585 83% tcaaaatgga -576 83% cctaaaaaaa -596 82% 
BARHL2 ttaaaatgga -585 85% tcaaaatgga -576 85% cctaaaaaaa -596 81% 
NOTO  ctccatttta -584 81% ctccattttg -575 82% ctccattttt -586 81% 
YY1  taaaatggagct -584 85% caaaatggagct -575 89% taacatggtgag -617 81% 
SOX10  catttt -583 81% catttt -574 81% catggt -614 80% 
FOXD2  gctaata -575 84% aacaaca -563 86% aaaaatg -586 83% 
GSX1  tgttattagc -575 88% tgttgttagc -566 79% cctaaaaaaa -596 81% 
MNX1  gctaataaca -575 89% gctaacaaca -566 81% tctcctaaaa -599 80% 
STAT5 aatccccagag -560 90% aatccccagag -551 90% ttttttaggag -598 83% 
E2F6  gggagtgaggc -549 85% gggagtgagac -540 85% tggagggaaaa -581 95% 
SOX10  ccgtgt -539 84% ccgtgt -530 84% cttttt -574 82% 
HIC1  acgccaaaa -534 81% acgccaaaa -525 81% acgccaggc -569 82% 
HIC2  acgccaaaa -534 80% acgccaaaa -525 80% acgccaggc -569 82% 
THAP1  acgccaaaa -534 80% acgccaaaa -525 80% tttccctcc -580 87% 
NFIX  cacgccaaa -533 94% cacgccaaa -524 94% cacgccagg -568 92% 
HES1  gccacgccaa -532 86% gccacgccaa -523 86% accacgccag -567 82% 
MGA  tggcgtgg -531 80% tggcgtgg -522 80% tggcgtgg -566 80% 
ARNT  ggcgtg -530 92% ggcgtg -521 92% ggcgtg -565 92% 
EGR1  gcccctgccacgcc -530 87% gcccctgccacgc -521 87% ccgccaccaccac -563 85% 
PAX2  tgccacgc -529 88% tgccacgc -520 88% caccacgc -564 81% 
THAP1  ctgccacgc -529 83% ctgccacgc -520 83% ccgccacca -558 86% 
KLF16  gcccctgccac -527 81% gcccctgccac -518 81% gccaccaccac -562 82% 
SP2  ccactgcccctgcca -526 80% cctctgcccctgcc -517 82% tgcccgccacca -561 81% 
EGR1  ccactgcccctgcc -525 87% cctctgcccctgcc -516 88% tgcccgccaccac -560 85% 
NFIX  aggggcagt -522 82% aggggcaga -513 82% cccgccacc -557 83% 
E2F6  cagtgggaatg -517 82% cagagggaatg -508 85% tggcgggcacc -555 84% 
HIC2  attcccact -516 88% attccctct -507 83% gtgcccgcc -554 97% 
THAP1  attcccact -516 81% attccctct -507 82% gtgcccgcc -554 90% 
ZEB1  tcgtacctg -499 89% tcgtacctg -490 89% gggcacctg -551 83% 
ID4  cgtacctggg -498 80% cgtacctggg -489 80% tacaggtgcc -550 84% 
TCF3  cgtacctggg -498 83% cgtacctggg -489 83% ggcacctgta -550 97% 
TCF4  cgtacctggg -498 86% cgtacctggg -489 86% ggcacctgta -550 97% 
HIF1A  gtacctgg -497 80% gtacctgg -488 80% acaggtgc -549 81% 
SNAI2  cccaggtac -497 85% cccaggtac -488 85% tacaggtgc -549 98% 
HIC1  gtgcccagg -494 86% gtgcccagg -485 86% gtcccagct -540 86% 
HIC2  gtgcccagg -494 96% gtgcccagg -485 96% gtcccagct -540 86% 
MZF1  tgggca -492 81% tgggca -483 81% ctggga -539 83% 
NFIC  tgggca -492 85% tgggca -483 85% ctggga -539 79% 
ISL2  gcactcta -489 87% gcactctg -480 85% ctactcag -533 81% 
E2F6  gacagggaact -476 80% gacagggaact -467 80% aggcaggagga -518 87% 
MEIS3  aagacagg -471 89% aagacagg -462 89% gaggcagg -519 81% 
CEBPA  cttacagaaga -467 80% cttacagaaga -458 80% attgcttgagc -508 82% 
SNAI2  gtaaggtgc -461 87% gtaaggtgc -452 87% ggcaggagg -517 79% 
TCF4  agcaccttac -461 79% agcaccttac -452 79% tcctcctgcc -517 82% 
TFAP2A  tgctcagagca -455 80% tgctcagagca -446 80% gggctcaagca -506 84% 
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TFAP2A  tgctctgagca -455 80% tgctctgagca -446 80% tgcttgagccc -506 79% 
TFAP2C tgctcagagca -455 81% tgctcagagca -446 81% gggctcaagca -506 83% 
TFAP2C  tgctctgagca -455 80% tgctctgagca -446 80% tgcttgagccc -506 80% 
NRL  agcaggctgag -448 80% agcaggctgag -439 80% ttactgcagcc -485 80% 
ZFX  cacagctcagcctg -446 81% acaggctcagcct -437 83% cctgcctcagcctc -525 85% 
PITX1  ctcagcct -445 79% ctcagcct -436 79% ttgagccc -503 84% 
MEIS3  ttcacagc -438 82% ttcacagg -428 82% gtggcacg -466 85% 
ESRRG  ccaagttcac -435 84% ccaagttcac -425 84% ccaagatcgt -473 80% 
NFIA  ctttccaagt -431 83% ctttccaagt -421 83% cgtgccactg -466 81% 
NFIX  ctttccaag -430 90% ctttccaag -420 90% cgtgccact -466 88% 
NFIC  ttggaa -429 93% ttggaa -419 93% agtggcacg -466 81% 
NFIC  ttggaa -429 93% ttggaa -419 93% tgcactccag -458 82% 
TEAD1  atctttccaa -429 80% atctttccaa -419 80% gcactcca -457 85% 
TCF3  gatctgccgc -422 80% gatctgcctc -412 84% aggctggagt -455 79% 
NFIX  ggcggcaga -420 84% ggaggcaga -410 85% cactccagc -456 83% 
E2F6  gggaaggaatg -408 83% gggaaggaatg -398 83% aggctggagtg -456 83% 
MZF1  ggggga -401 96% ggggga -391 96% gggtga -445 81% 
EGR1  cccccacttccccc -400 82% cccccacttccccc -390 82% gtgctgccgatgcc -407 80% 
HIF1A  ggaagtgg -397 80% ggaagtgg -387 80% ccacgtgc -391 97% 
SMAD2 aggtctgccagcc -386 84% aggtctgccagcc -376 84% cactctgtcaccc -445 86% 
USF2  agcctgtggct -377 82% agcctgtggct -367 82% tcaaataa -422 81% 
NOTO  acaaatagcc -370 79% acaaatagcc -360 79% tcaaataata -422 81% 
MEF2A  gctacaaatagc -369 91% gctacaaatagc -359 91% aataataataat -419 82% 
MEF2B  gctacaaatagc -369 92% gctacaaatagc -359 92% aataataataat -419 81% 
MEF2D  gctacaaatagc -369 91% gctacaaatagc -359 91% aataataataat -419 82% 
RAX  tacaaatagc -369 83% tacaaatagc -359 83% ctcaaataat -423 86% 
ISL2  acaaatag -368 79% acaaatag -358 79% tcaaataa -422 80% 
ISX  acaaatag -368 80% acaaatag -358 80% tcaaataa -422 82% 
FOXD2  acaaata -367 90% acaaata -357 90% tcaaata -422 82% 
FOXL1  acaaata -367 90% acaaata -357 90% tcaaata -422 83% 
MEOX2  agtcatcgct -360 80% agcaatgact -350 84% aataataatg -416 82% 
PAX2  agtcatcg -358 83% agtcattg -348 94% tgtcaccc -445 84% 
JDP2  gatgactgcatc -357 80% aatgactacatc -347 79% cagagtgagaccc -439 79% 
SOX10  ccttgt -338 92% ccttgt -328 92% cattat -412 81% 
CDX1  tccatacaa -336 80% tccatacaa -326 80% ataataatg -415 86% 
TEAD1  agcatcccgt -328 84% cgcatagcaa -313 80% cacattatta -414 85% 
TEAD4  agcatcccgt -328 79% cgcatagcaa -313 81% cacattatta -414 80% 
HIF1A  gtgcgtgt -318 90% atgcgtgt -308 87% gcacgtgg -391 96% 
ARNT  tgcgtg -317 100% tgcgtg -307 100% cacgtg -390 80% 
NEUROD cacacacgca -317 81% cacacacgca -307 81% accacgtgcc -392 84% 
TCFL5  cacacacgca -317 80% cacacacgca -307 80% accacgtgcc -392 97% 
TCFL5  tgcgtgtgtg -317 80% tgcgtgtgtg -307 80% ggcacgtggt -392 97% 
ARNT  cgtgtg -315 84% cgtgtg -305 84% cacgtg -390 80% 
ARNT  tgtgtg -313 85% tgtgtg -303 85% tgcctg -376 82% 
PAX2  gatcacac -312 81% gatcacac -302 81% ggtcaggg -385 85% 
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ARID3A  atcaca -311 79% atcaca -301 79% attaat -344 94% 
GATA5  tgatcaca -311 89% tgatcaca -301 89% taataaga -348 80% 
LHX4  gtgatcaa -310 84% ttgatcac -300 83% cttattaa -347 91% 
LHX4  ttgatcac -310 83% gtgatcaa -300 84% ttaataag -347 81% 
LHX8  ttgatcac -310 91% ttgatcac -300 91% cttattaa -347 84% 
LHX8  gtgatcaa -310 91% gtgatcaa -300 91% ttaataag -347 83% 
UNCX  ttgatcac -310 79% ttgatcac -300 79% cttattaa -347 89% 
ARID3A  atcaag -307 84% atcaaa -297 97% attaat -344 94% 
HIC2  ttcccctcc -302 80% atcccagtc -285 83% ctgccatac -367 82% 
MYOD1  tacacctgtctgt -278 94% tacaccagtctgt -268 82% ggcagctgttgtt -363 98% 
SOX10  ctgtct -276 82% cagtct -266 81% tgttgt -357 82% 
TCF12  gacaggtgtat -275 92% gactggtgtac -265 80% aacagctgcca -364 98% 
TCF3  tacacctgtc -275 97% tacaccagtc -265 86% aacagctgcc -363 94% 
TCF4  tacacctgtc -275 98% tacaccagtc -265 87% aacagctgcc -363 93% 
PAX2  cgtcgctg -250 85% catcgctg -240 79% tgttattc -354 82% 
SNAI2  ttctagtgc -234 79% ttctagtgc -224 79% ggcagctgt -363 79% 
RFX1  ggttgccc -210 89% ggttgccc -201 89% tgttgtta -357 82% 
SNAI2  tgcaggttg -207 92% tgcaggttg -198 92% aacagctgc -362 79% 
GCM2  ctgcaggt -205 88% ctgcaggt -196 88% atgggtgt -340 81% 
KLF1  gacccagccct -198 81% agccccagccc -190 81% aaagacaccca -339 83% 
MEIS3  ttggcagg -190 91% ttggcagg -181 91% aagacacc -337 85% 
KLF4  ggggcttggc -187 87% ggggcttggc -178 87% tgggtgtctt -339 81% 
ELK4  tagcttccttg -165 81% tagcttccttg -156 81% ttgtttctggc -324 79% 
ERG  caaggaagct -164 80% caaggaagct -155 80% acagtatgtg -290 81% 
EGR1  gccacgccccattc -154 82% gctacgcccctttc -145 85% tgccctccccctag -250 83% 
KLF16  gccacgcccca -154 91% gctacgcccct -145 89% tgccctccccc -250 83% 
KLF4  ggggcgtggc -154 98% ggggcgtagc -145 92% ggggagggca -250 80% 
SP2  gccacgccccattct -154 83% gctacgcccctttc -145 84% tgccctccccctag -250 87% 
THAP1  gagcccaga -142 82% gagcccgga -133 84% ttgccctcc -251 92% 
NFIX  ggagcccag -141 87% ggagcccgg -132 84% gagggcaag -252 85% 
KLF16  gctcctccctc -137 79% gctcctccctc -128 79% gccctccccct -249 80% 
E2F4  aagagggagga -135 79% aggagggagga -126 84% tagggggaggg -248 80% 
E2F6  aagagggagga -135 92% aggagggagga -126 95% tagggggaggg -248 83% 
MZF1  ggagga -135 84% ggagga -126 84% ggggga -245 96% 
THAP1  cctccctct -134 84% cctccctcc -125 85% cctccccct -247 80% 
NFIA  cttgcaaaag -121 81% cctgcaaagg -112 81% agggccaaca -209 83% 
NFIX  ttttgcaag -120 82% ctttgcagg -111 79% ccagccata -197 85% 
SOX10  ctttgt -99 100% ctctgt -95 86% cagtct -187 81% 
KLF1  ggccccgcccc -93 89% agccccgcccc -84 88% acacacacaca -159 79% 
EGR1  gccccgcccccaac -92 88% gccccgcccctgg -83 89% cacacacacacac -159 80% 
KLF16  gccccgccccc -92 98% gccccgcccct -83 94% cacacacacac -160 80% 
SP8  gccccgccccca -92 94% gccccgcccctg -83 84% cacacgcacaca -169 84% 
THAP1  ccgccccca -89 90% ccgcccctg -80 81% tctcccagc -193 80% 
EGR1  tgcctggccacgcc -78 81% cccctggtcacgc -77 79% ccccaacacacac -153 80% 
KLF12  ggccacgcctcctcc -73 87% ggtcacgcctcctc -72 80% caacacacaca -153 81% 
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KLF14  ggccacgcctcctc -73 93% ggtcacgcctcctc -72 91% gcccccgcccccc -144 86% 
EGR1  gccacgcctcctcc -72 92% gtcacgcctcctca -71 89% cccccgcccccca -145 82% 
KLF16  gccacgcctcc -72 94% gtcacgcctcc -71 88% ccccgcccccc -143 81% 
SP2  gccacgcctcctcct -72 87% gtcacgcctcctca -71 84% cccccgcccccca -146 93% 
SP8  gccacgcctcct -72 94% gtcacgcctcct -71 86% gcccccgccccc -142 83% 
MZF1  ggagga -64 84% tgagga -63 88% cggggg -137 85% 
FOXD2  gccaata -58 87% gccaata -57 87% acacaca -120 83% 
FOXL1  gccaata -58 85% gccaata -57 85% acacaca -120 81% 
FOXO4  gccaata -58 79% gccaata -57 79% aaacaca -122 79% 
EGR1  gctcctccttcggc -53 85% gctcctccctcggc -52 88% aagcagcccccgc -139 88% 
TFAP2A ccgccgaaggag -49 80% ctccctcggcgg -48 81% caccggagggcg -109 87% 
INSM1  ggcctgggagct -24 79% ggcctgggagct -24 79% aggcaggggaca -96 81% 
TFAP2A agctcccaggcc -24 84% ggcctgggagct -24 81% cgccctccggtg -109 87% 
TFAP2B  agctcccaggcc -24 82% ggcctgggagct -24 80% caccggagggcg -109 86% 
TFAP2B  ggcctgggagct -24 80% agctcccaggcc -24 82% cgccctccggtg -109 84% 
TFAP2C  agctcccaggcc -24 82% ggcctgggagct -24 80% caccggagggcg -109 85% 
TFAP2C  ggcctgggagct -24 80% agctcccaggcc -24 82% cgccctccggtg -109 84% 
ZFX  agctcccaggcctc -24 90% agctcccaggcct -24 90% ctgtcccctgcctc -97 81% 
MZF1  ctggga -21 83% ctggga -21 83% agggga -94 95% 
E2F6  gggagcgaggc -15 85% gggagtgaggc -15 85% cagaggcaggg -92 79% 
EGR1  gcctcgctccctcc -15 88% gcctcactccctcc -15 87% cccctgcctctggt -93 82% 
KLF16  ctccctcccat -9 80% ctccctcccat -9 80% ccccagcctcc -70 82% 
SP2  ctccctcccataagc -9 83% ctccctcccataaa -9 82% cccctgcctctggt -93 82% 
MZF1 ttatgggagg -6 85% ttatgggagg -6 85% ggaggctggg -70 79% 
EGR1  gccctgccctctcc 4 88% accctaccctctcc 4 85% cctcctccccagcc -67 88% 
KLF4  agggcagggc 4 88% agggtagggt 4 85% aggctgggga -68 83% 
SP2  gccctgccctctcct 4 89% accctaccctctcct 4 82% cctcctccccagcc -68 84% 
CTCF  gagccaggagaggg
caggg 
5 86% gagccaggagagggt
aggg 
5 82% gggcctgggggagca -42 81% 
EGR1  tgccctctcctggc 8 81% taccctctcctggc 8 81% gagcctcctcccca -64 81% 
MZF1  ggagga 22 84% agagga 22 83% ggagga -61 84% 
E2F6  cggaggaaaag 30 82% tggaggaaaag 26 86% agcagggagcc -49 82% 
TFAP2A  ggccggaggaa 33 81% ttcctccagcg 29 82% aggctcgggct -56 87% 
TFAP2B ggccggaggaa 33 83% ttcctccagcga 29 80% agcccgagcct -56 85% 
TFAP2B ttcctccggcc 33 82% cgctggaggaa 29 79% aggctcgggct -56 83% 
TFAP2C  ggccggaggaa 33 84% cgctggaggaa 29 81% aggctcgggct -56 87% 
TFAP2C  ttcctccggcc 33 81% ttcctccagcg 29 79% agcccgagcct -56 88% 
E2F4  aggccggagga 34 84% tcgctggagga 30 82% gcccggggagg -28 81% 
MZF1  ggagga 34 84% ggagga 30 84% ggggga -39 96% 
EGR1  attcctcctcctgg 49 85% atccctcctcctgg 45 86% gggcctccccccg -21 82% 
SP2  attcctcctcctggt 49 84% atccctcctcctggt 45 87% gggcctccccccg -21 84% 
MZF1  ggaggaggaa 50 88% ggaggaggga 46 84% ggcgggggga -16 87% 
MZF1  ggagga 54 84% ggagga 50 84% gggggg -15 84% 
GCM2  ctcctggt 56 81% ctcctggt 52 81% aggcgggg -13 81% 
GCM1  cctggtggtcc 58 79% cctggtggtcc 54 79% ggtgcgggagg -8 81% 
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GCM2  ctggtggt 59 85% ctggtggt 55 85% gtgcggga -6 90% 
SPIB  tagggaa 70 84% tggggaa 66 92% tgcggga -6 79% 
PPARG ggtgggcacaggg 79 84% agtgggcacagg 75 81% ggcgggcagagg 6 83% 
NFIX  tgtgcccac 84 90% tgtgcccac 80 90% tctgcccgc 11 85% 
HIC2  gtgcccacc 85 100% gtgcccact 81 99% ctgcccgcc 12 92% 
THAP1  gtgcccacc 85 88% gtgcccact 81 88% cttccctct 5 88% 
EGR1  caccctctctcttc 90 81% ctctctcctccttc 90 85% cccccgcctcccg -14 86% 
GATA4  ccctctctctt 92 84% ctctctctcct 88 80% ccttccctctg 4 80% 
EGR1  ccttcagctcctcc 103 79% ccttcaactcctcc 99 79% ccgcctcccgcac -11 87% 
EGR1  gctcctccctcttc 109 86% actcctccctcttc 105 85% tgcccgcctccgc 13 93% 
SP2  gctcctccctcttcc 109 89% actcctccctcttcc 105 86% tgcccgcctccgc 13 91% 
E2F4  aagagggagga 111 79% aagagggagga 107 79% gagggggagga 27 82% 
E2F6  aagagggagga 111 92% aagagggagga 107 92% gagggggagga 27 85% 
MZF1  ggagga 111 84% ggagga 107 84% ggagga 27 84% 
THAP1  cctccctct 112 84% cctccctct 108 84% cctccccct 28 80% 
MZF1 gaagagggag 113 80% gaagagggag 109 80% agagggggag 29 91% 
SP2  ctccctcttccaggc 113 80% ctccctcttccagg 109 80% cctccgcctcctcc 19 93% 
GABPA  ctggaagaggg 115 82% ctggaagaggg 111 82% gcggaggcggg 15 81% 
E2F6  tggttggagga 136 79% gggttggagga 132 82% gagccggagag 37 84% 
KLF16  tccacaccacc 160 83% cacacaccacc 159 84% gctcctccccc 44 87% 
MZF1  tgtgga 160 81% gtggga 156 81% ggggga 30 96% 
KLF1  cacaccaccct 162 85% cacaccaccct 161 85% ggctcctcccc 43 81% 
KLF4  agggtggtgt 163 89% agggtggtgt 162 89% ggggaggagc 44 87% 
THAP1  ccacccttc 166 81% ccaccctgc 165 79% cctccccct 47 80% 
E2F6  gagaggaaatt 178 80% gagaggaaatt 177 80% gcgagggaggg 52 94% 
E2F6  gggagagagga 182 85% gggagagagga 181 85% gcgagggagcg 60 92% 
EGR1  ctctctcccacctc 184 79% ctctctcccacctc 183 79% ccctcgccgcctcc 64 90% 
E2F4  aggtgggagag 186 84% aggtgggagag 185 84% aggcggcgagg 65 82% 
EGR1  ctcccacctcccgg 188 81% ctcccacctcctgg 187 89% tcgccgcctccccc 67 86% 
SP2  ctcccacctcccggt 188 87% ctcccacctcctgg 187 88% tcgccgcctccccc 67 85% 
MZF1  gtggga 189 81% gtggga 188 81% aggggg 76 83% 
MZF1 ggaggtggga 189 84% ggaggtggga 188 84% ggagggggag 74 97% 
FIGLA  cccacctccc 190 80% cccacctcct 189 82% cccccgtgtc 82 79% 
HIF1A  ggaggtgg 191 80% ggaggtgg 190 80% ccccgtgt 83 80% 
ZBTB7B  aggaccaccggg 197 87% aggaccaccagg 196 85% tcgcccaccact 206 85% 
ZBTB7C  aggaccaccggg 197 88% aggaccaccagg 196 86% tcgcccaccact 206 86% 
ZBTB7A  aaggaccaccgg 198 85% aaggaccaccag 197 82% gtcgcccaccac 205 86% 
PPARG ctgggaaaaggacc 202 79% ctggggaaagga 201 82% gagggacacggg 81 81% 
ARNTL  gctcacttgt 216 80% gctcacttgt 215 80% ggacacgggg 83 81% 
USF1  ctcacttgtcc 217 81% ctcacttgtcc 216 81% cccccgtgtcc 82 81% 
HES2  gtgggacaagtga 218 88% gtgggacaagtga 217 88% gagggacacggg 83 83% 
ID2  acaagtga 218 84% acaagtga 217 84% acacgggg 83 82% 
MLXIP  tcacttgt 218 84% tcacttgt 217 84% ccccgtgt 83 84% 
ARNT  caagtg 219 83% caagtg 218 83% cccgtg 84 83% 
ARNT  cacttg 219 83% cacttg 218 83% cacggg 84 83% 
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MEIS3  gggacaag 221 83% gggacaag 220 83% gggacacg 86 83% 
E2F6  gggtgggacaa 222 83% gggtgggacaa 221 83% gggagggacac 87 87% 
KLF14  tgtcccaccccctc 223 84% tgtcccaccccctc 222 84% tgtccctcccctct 88 82% 
EGR1  gtcccaccccctct 224 93% gtcccaccccctcc 223 95% ctccctcccctcct 126 81% 
KLF16  gtcccaccccc 224 89% gtcccaccccc 223 89% ctccctcccct 126 83% 
KLF4  ggggtgggac 224 91% ggggtgggac 223 91% ggggagggag 126 80% 
SP2  gtcccaccccctctc 224 93% gtcccaccccctcc 223 96% ctccctcccctcctc 126 90% 
SP8  gtcccaccccct 224 84% gtcccaccccct 223 84% gtccctcccctc 89 80% 
TBX5  gggtggga 225 87% gggtggga 224 87% aggggata 118 80% 
EGR1  cccaccccctctca 226 81% caccccctcccgtc 227 81% ccctcccctcctcc 128 83% 
SP8  cccaccccctct 226 86% cccaccccctcc 225 85% tcccctcctccc 131 80% 
SP2  ccccctctcatccgc 230 81% ccccctcccgtcag 229 80% tcccctcctccccg 131 90% 
EGR1  cggcatctccctcc 244 82% cggcaactccctcc 243 83% tcccctcctccccg 131 84% 
E2F6  aggagggagat 248 93% aggagggagtt 247 90% aggaggggagg 129 85% 
MZF1 gaaggaggga 251 80% gaaggaggga 250 80% ggaggggagg 129 90% 
MZF1 ggcgggggaa 286 91% ggcgggggaa 284 91% ggaggagggg 132 81% 
MZF1  ggggga 287 96% ggggga 285 96% agggga 131 95% 
EGR1  cccccgccccaatt 288 84% cccccgccccagtt 286 85% cctcctccccggct 134 86% 
KLF16  cccccgcccca 288 87% cccccgcccca 286 87% tcccctcctcc 131 84% 
KLF4  ggggcggggg 288 93% ggggcggggg 286 93% ggggaggagg 134 82% 
MZF1  cggggg 288 85% cggggg 286 85% ggagga 136 84% 
SP2  cccccgccccaattc 288 87% cccccgccccagtt 286 88% cctcctccccggct 134 83% 
MZF1  agagga 301 83% agagga 299 83% cgggga 139 97% 
EGR1  cctctgttcccgcc 302 79% cctctgtccccgcc 300 84% ccggctctccctct 142 80% 
E2F4  gggcgggaaca 306 98% gggcggggaca 304 91% agccggggagg 137 80% 
HIC2  gttcccgcc 307 87% gtccccgcc 305 89% ctccccggc 138 82% 
EGR1  ttcccgcccccttc 308 93% tccccgcccccttc 306 94% ggctctccctctca 144 83% 
E2F4  ccgggggaagg 317 84% ccgggggaagg 315 84% gagagggagag 146 82% 
E2F6  ccgggggaagg 317 80% ccgggggaagg 315 80% gagagggagag 146 93% 
THAP1  cttcccccg 318 81% cttcccccg 316 81% tctccctct 147 83% 
MZF1 gccgggggaa 319 81% gccgggggaa 317 81% tgagagggag 148 83% 
SPIB  gggggaa 319 80% gggggaa 317 80% agaggga 149 84% 
TFAP2A  ttcccccggct 319 85% ttcccccggcc 317 84% agtctcaggct 157 86% 
TFAP2A  agccgggggaa 319 81% aggccggggga 318 81% agcctgagact 157 85% 
TFAP2A  ttcccccggctt 319 81% ttcccccggcct 317 87% cgcccgaaagag 191 81% 
TFAP2B  ttcccccggct 319 83% ttcccccggcc 317 80% agtctcaggct 157 87% 
TFAP2C agccgggggaa 319 84% ggccgggggaa 317 80% agtctcaggct 157 86% 
EGR1  ccccggcttcctcc 322 82% ccccggcctcctcc 320 87% cgcccaccactgc 207 82% 
EGR1  tcccctgcctctcc 346 81% tcccctacctctcc 344 81% ccaccactgccag 210 82% 
NFIX  ctctccaat 354 85% ctctccagt 352 82% actgccagc 215 94% 
MZF1  tggaga 355 81% tggaga 353 81% tggggg 231 88% 
NFIC  ttggag 356 88% ctggag 354 84% ctggag 243 84% 
TFAP2A  ctccccggggct 371 89% agccccggagag 369 81% ccccccagcgct 226 85% 
TFAP2B  agccccggggag 371 87% agccccggagag 369 79% ccccccagcgct 226 82% 
TFAP2C  ctccccggggct 371 86% agccccggagag 369 79% ccccccagcgct 226 80% 
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EGR1  cccccccttcctct 395 81% tctctgtccccgcc 402 83% cccccacctcccc 279 86% 
SOX10  ctctgt 405 86% ctctgt 403 86% cattgg 273 84% 
HIC1  gtccccgcc 409 83% gtccccgcc 407 83% acgccccca 287 79% 
HIC2  gtccccgcc 409 89% gtccccgcc 407 89% acgccccca 287 82% 
KLF14  gtccccgccccctc 409 88% gtccccgccccctc 407 88% tcccacgccccca 286 89% 
KLF16  tccccgccccc 410 93% tccccgccccc 408 93% cccacgccccc 288 97% 
KLF4  ggggcgggga 410 93% ggggcgggga 408 93% ggggcgtggg 289 93% 
SP2  tccccgccccctccc 410 97% tccccgccccctcc 408 97% cccccacctcccc 278 90% 
SP8  tccccgccccct 410 91% tccccgccccct 408 91% cccacctcccca 279 81% 
E2F6  gggagggggcg 414 83% gggagggggcg 412 83% gcgtgggaaaa 292 91% 
MZF1 ggagggggcg 414 86% ggagggggcg 412 86% ggcgtgggaa 291 81% 
SP8  gccccctcccct 415 83% gccccctcccct 413 83% cccccacctccc 281 81% 
EGR1  ccccctcccctgga 416 89% ccccctcccctgg 414 88% ccttttcccacgcc 291 86% 
KLF4  ggggaggggg 416 88% ggggaggggg 414 88% aggacggggt 302 84% 
SP2  ccccctcccctggac 416 88% ccccctcccctgg 414 89% cccacgcccccac 284 83% 
ZEB1  cctcccctg 419 87% cctcccctg 417 87% ccgcacctg 317 97% 
MZF1  agggga 421 95% agggga 419 95% tggggt 313 81% 
KLF1  gactccgccct 428 87% ggctccgccct 426 88% aaccccgtcct 302 80% 
SP2  actccgccctcctcc 429 89% gctccgccctcctc 427 92% ttcccacgccccca 286 80% 
SP8  actccgccctcc 429 81% gctccgccctcc 427 82% cccacgccccca 287 95% 
THAP1  ccgccctcc 432 90% ccgccctcc 430 90% acgccccca 287 83% 
SP2  cgccctcctcccagc 433 87% cgccctcctcccg 431 88% accccgtccttttcc 297 81% 
MZF1  ggagga 438 84% ggagga 436 84% tgcgga 321 81% 
KLF16  tcccagcccct 441 83% tcccggcccct 439 81% gaaccgccccc 329 89% 
KLF4  ggggctggga 441 82% ggggccggga 439 81% ggggcggttc 330 84% 
SP2  tcccagcccctcccc 441 86% tcccggccccttc 439 86% cccccactccgca 319 79% 
KLF4  ggggaggggc 446 94% gggaaggggc 444 82% ggagtggggg 324 81% 
HIC2  gttcccctc 458 80% ttcccctcc 456 80% gcccccact 326 79% 
SPIB  aggggaa 458 95% aggggaa 456 95% tgcggag 321 79% 
SP2  tcccctcctagcatc 459 80% tcccctcctcgcat 457 84% gaaccgcccccac 325 84% 
ETV5  aggggatgct 468 81% aggggatgcg 466 82% tcgggaagcc 338 81% 
SPIB  aggggat 471 82% aggggat 469 82% tcgggaa 338 89% 
SP2  tcccctctcttccct 472 81% tcccctctcctccct 470 84% cccccacctccata 372 84% 
MZF1 ggagggaaga 479 80% ggagggagga 477 84% ggaggtgggg 376 81% 
THAP1  cttccctcc 480 89% cctccctcc 478 85% cctccataa 372 83% 
TBX15  aggaggga 482 79% aggaggga 480 79% aggtgggg 378 83% 
TBX5  aggaggga 482 79% aggaggga 480 79% aggtgggg 378 86% 
KLF4  agggaggagg 484 83% agggaggagg 482 83% gaggtggggg 377 84% 
E2F6  agcagggagga 486 84% agcagggagga 484 84% aggtggggggc 378 80% 
MZF1  ggagga 486 84% ggagga 484 84% tggggg 381 88% 
THAP1  cctccctgc 487 82% cctccctgc 485 82% cagcccccc 382 80% 
THAP1  tctccctca 496 88% tctccctca 494 88% tggcccagc 393 79% 
GCM2  ctgaggga 498 81% ctgaggga 496 81% gtgctggg 396 87% 
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S-6: List of primers used in this work 
PRIMER SEQUENCE 
Region S4 Forward agctatgaagccgttctctgctc 
Region S4 Reverse agcactcctacctacaagtgcacag 
Region S3 Forward tccttccttccctaccttgcc 
Region S3 Reverse gcccagagacagacagacagacat 
Region S2 Forward acaccttctgtgggctgtatagcgg 
Region S2 Reverse gtctaacccacagcctgccct 
Region S1 Forward catgcaagcaagggaggtgtc 
Region S1 Reverse gtggctcagtggttgagccc 
Pgl3-S3(-319/+595) Forward cccagtgcaagtgcaggtgcgtgtgtgatcaaggagggg 
Pgl3-S3(-319/+595) Reverse cccctccttgatcacacacgcacctgcacttgcactggg 
Pgl3-S3(+113/+595) Forward ccagtgcaagtgcaggtgcccctcttccaggctgtcc 
Pgl3-S3(+113/+595) Reverse ggacagcctggaagaggggcacctgcacttgcactgg 
Pgl3-S3(+424/+595) Forward cccagtgcaagtgcaggtgcctggactccgccctc 
Pgl3-S3(+424/+595) Reverse gagggcggagtccaggcaacctggcacttgcactggg 
Mouse Hprt Forward agcgtcgtgattagcgatga 
Mouse Hprt Reverse tccaaatcctcggcataatga 
Mouse Ncx2 Forward agtggatgatgaagagtatgagaagaag 
Mouse Ncx2 Reverse ttggttgagtagcagagctgaga 
Rat Hprt Forward gaaagaacgtcttgattgttgaagatat 
Rat Hprt Reverse gagaggtccttttcaccagcaa 
Rat Ncx2 Forward cagcaccttctacgtggattacc 
Rat Ncx2 Reverse gccctcgctgtactcataatcg 
Human Mgmt Forward ggtccggagcccctgat 
Human Mgmt Reverse gctggtggaaataggcattca 
Human Hprt Forward aggaggccgcacacctttcc 
Human Hprt Reverse caaggcgtggctgggctctc 
Human Ncx2 Forward gaccagtcaacaggggacat 
Human Ncx2 Reverse cgaccttgaccatctttgga 
A-F1 gagtttaggttttgttgtgatgatgg 
A-F2 ggttttttgagtgttggggttatag 
A-R1 caactcaacctactcaaaacacc 
B-F3 tgttttttgtaaggtgttttgagtagg 
B-F4 gagttgtgaatttggaaagatttgt 
B-R2 cttaacaaaactaaatctacaaattaccc 
C-F5 gggtaatttgtagatttagttttgttaag 
C-R3 cacaaaaaaagtaaaaaaaaaaccacc 
C-R4 caaaaacaacctaaaaaaaaaaaaaac 
D-F6 agttttttttttttttaggttgtttttg 
D-R5 gctaaactcttacctacttacaac 
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D-R6 ctcaaaaaaccccctacac 
E-F7 ggttgtaaagtaggtaagagtttag 
E-R7 cctcctccaaatccctatacatc 
E-R8 ctataaacaaaaccaaccccaaaaaatc 
Pgl3-S3(+113/+595)Mutsp1  ctgcctctccaatctagccactagtccggggctgctttctcag 
Pgl3-S3(+113/+595)Mutsp1  ctgagaaagcagccccggactagtggctagattggagaggc
ag 
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